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ABSTRACT 
Tramadol and tapentadol are synthetic, structurally related and commonly 
prescribed opioids for the treatment of moderate to severe pain. Tramadol is one of the 
most prescribed opioids, while tapentadol is a more recently marketed drug. The 
clinical interest of these opioids is associated with their high analgesic efficiency, 
combined with the low incidence of adverse effects. Regarding their mechanism of 
action, both are mu-opioid receptor agonists and neurotransmitter reuptake inhibitors. 
The synergetic interactions of these mechanisms of action increase the analgesic 
activity and minimize the adverse effects. Despite the structural and mechanistic 
similarity between both drugs, tapentadol is considered an update over tramadol. 
Tramadol inhibits noradrenaline and serotonin reuptake and requires metabolization to 
exert full pharmacological activity, whereas tapentadol does not require metabolic 
activation and its action is predominantly through inhibition of noradrenaline reuptake. 
Although tramadol and tapentadol are effective in pain relief and show a low rate 
of adverse reactions, the incidence of poisoning cases, including fatal intoxications, as 
well as cases of addiction, have been increasing in parallel with the increase in their 
consumption. However, the toxicity mechanisms are not fully understood yet, and few 
studies are available on the comparison of adverse events and toxicological profiles 
between these two opioids. Concerning tapentadol in particular, literature is still scarce, 
since it is a more recently marketed drug. In this sense, the main objective of the present 
work was to perform a comparative evaluation of tramadol and tapentadol acute toxicity, 
as well as to contribute to the clarification of the mechanisms underlying toxicity. 
Considering the central action of these opioids, one specific objective was the in 
vitro evaluation of potential neurotoxicity, using the SH-SY5Y neuroblastoma cell line 
as a model. SH-SY5Y undifferentiated cells were exposed to increasing tramadol and 
tapentadol concentrations up to 600 µM. Upon tramadol/tapentadol incubation for 48 
hours, cell viability, cell death mechanisms, mitochondrial integrity, metabolic 
alterations and oxidative stress damage were assessed. The results obtained were 
analysed and compared with non-treated cells (control), and a comparative discussion 
of the toxicological damage triggered by tramadol and tapentadol was performed. SRB 
and MTT assays have shown that that tapentadol caused a higher decrease in biomass 
and a in mitochondrial metabolic activity, comparing to tramadol. However, both 
opioids caused toxicity and decreased cell viability, as analysed through the trypan blue 
 xx 
exclusion method. Concerning oxidative stress damage, after exposure to tramadol or 
tapentadol no alterations in lipid peroxidation or protein oxidation were observed, 
suggesting that the toxicity resulting from the exposure to both opioids was probably 
not due to oxidative damage. On the other hand, a bioenergetic crisis, more evident 
when the cells were treated with tapentadol, characterized by an increase in intracellular 
glucose levels, together with a decrease in ATP content and an increase in lactate 
production, was observed as a result of the changes in the expression of genes that 
encode for energetic metabolism enzymes (such as LDH (lactate dehydrogenase), 
NDUFS1 (Fe-S protein 1 of NADH dehydrogenase), CKB (creatine kinase B), PDK3 
(pyruvate dehydrogenase kinase 3) and ALDOC (aldolase C)). Therefore, the results 
showed that, in this in vitro cell model, tapentadol caused higher toxicity, leading to a 
bioenergetic crisis and increased cell death, when compared to tramadol. In addition, 
necrosis was the main mechanism of death after exposure to both opioids, and no 
alterations in mitochondrial membrane potential or in cytochrome c release were 
observed, with only a minor increase in the activity of caspases being detected.  
In addition to the in vitro assays, in vivo acute exposure assays were performed 
using male Wistar rats. In vivo assays have allowed a more complete and 
comprehensive study of the toxicological profile of these opioids. 10, 25 or 50 mg/kg 
tramadol and tapentadol doses (delivered in 1 ml of 0.9% NaCl), corresponding to a 
low effective analgesic dose, an intermediate dose and the maximum recommended 
daily dose, were intraperitoneally administered. A control group of animals, 
intraperitoneally injected with 1 ml of 0.9% NaCl, was included in the study. 24 hours 
after administration, biochemical alterations, as well as histological alterations and 
oxidative damage, were assessed in brain, lung and heart tissues. Regarding the analysis 
of biochemical alterations in serum samples, both drugs caused an increase in the 
AST/ALT (aspartate aminotransferase/alanine aminotransferase) ratio, as well as an 
increase in the activity of LDH (lactate dehydrogenase), CK (creatine kinase) and CK-
MB (creatine kinase-MB isoform) enzymes. An increase in protein oxidation, in 
pulmonary and cardiac tissues, was observed. In the histological analysis, alterations in 
brain cortex samples were observed, such as the presence of swollen neurons, lower 
definition of nuclear membranes and the presence of degenerated neurons. In lung 
tissue, the presence of intra-alveolar hemorrhage and alveolar collapse was observed. 
Cardiac toxicity was also observed, characterized by the presence of inflammatory 
infiltrates and loss of cardiomyocyte striation, which, together with the biochemical 
 xxi 
changes detected, suggested that both opioids cause cardiac damage. Taken as a whole, 
the in vivo results showed that tapentadol led to more prominent toxic effects than the 
exposure to tramadol. 
In conclusion, the results of the present study showed that tramadol and tapentadol 
cause toxicity, even in an acute exposure context, with tapentadol causing more evident 
toxic damage in the models used. The results presented are an important starting point, 
which should be complemented with chronic exposure assays, as well as with 
simultaneous exposure assays using other drugs. The understanding of the molecular 
and biochemical alterations triggered by opioids will allow the recognition and better 
clarification of adverse reactions, and it represents an additional tool for the evaluation 
of intoxication cases due to exposure to these opioids. 
The results within this thesis underline the recommendation for a careful and 
conscious tramadol and tapentadol prescription, and that opioid selection should be 
adjusted individually in order to optimize therapeutic strategies and minimize adverse 
effects. 
 
Keywords: Toxicity assays, neurotoxicity, pneumotoxicity, cardiotoxicity, acute 
exposure, in vivo, in vitro, opioids, tapentadol, tramadol. 
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RESUMO 
O tramadol e o tapentadol são opioides sintéticos, estruturalmente relacionados e 
amplamente prescritos para o tratamento da dor moderada a severa. O tramadol é 
atualmente um dos opioides mais prescritos no mundo, ao passo que o tapentadol é um 
fármaco de introdução mais recente no mercado. O interesse clínico destes dois 
opioides encontra-se associado à sua elevada eficácia analgésica, aliada à baixa 
incidência de efeitos adversos. No que concerne ao seu mecanismo de ação, ambos 
combinam o agonismo dos recetores mu-opioides com a inibição da recaptação de 
neurotransmissores. Estes mecanismos de ação interagem de forma sinérgica, 
aumentando a atividade analgésica e minimizando os efeitos adversos. Apesar das 
semelhanças estruturais e dos seus mecanismos de ação, o tapentadol é considerado 
uma atualização em relação ao tramadol. O tramadol, que atua através da inibição da 
recaptação de noradrenalina e de serotonina, requer metabolização para exercer 
atividade farmacológica plena, enquanto o tapentadol não requer ativação metabólica e 
atua principalmente através da inibição da recaptação de noradrenalina. 
Embora, tal como referido anteriormente, tanto o tramadol como o tapentadol 
sejam efetivos no tratamento da dor, e apresentem uma baixa taxa de reações adversas 
reportadas, a incidência de intoxicações, inclusive de intoxicações fatais, assim como 
de casos de dependência, tem aumentado paralelamente ao aumento do seu consumo. 
No entanto, os mecanismos subjacentes à toxicidade observada não são ainda 
totalmente conhecidos, e existe pouca informação disponível sobre a comparação dos 
eventos adversos e perfis toxicológicos entre estes dois opioides. Em particular para o 
tapentadol, a literatura é ainda escassa, devido ao facto de ser um fármaco mais 
recentemente introduzido no mercado. Neste sentido, o principal objetivo do presente 
trabalho foi o de efetuar uma avaliação comparativa da toxicidade resultante da 
exposição aguda a tramadol e a tapentadol, assim como contribuir para o 
esclarecimento dos mecanismos subjacentes à toxicidade. 
Considerando a ação destes opioides ao nível do sistema nervoso central, um dos 
objetivos específicos do trabalho compreendeu a avaliação in vitro da eventual 
neurotoxicidade, utilizando como modelo a linha celular de neuroblastoma SH-SY5Y. 
Expuseram-se células indiferenciadas desta linha a concentrações crescentes de 
tramadol e tapentadol, até 600 µM. Após 48 horas de exposição, avaliaram-se a 
viabilidade celular, os mecanismos de morte associados à diminuição da viabilidade 
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celular, assim como eventuais alterações mitocondriais, metabólicas e o aumento do 
stresse oxidativo. Os resultados obtidos foram analisados comparativamente aos 
obtidos em células não expostas a opioide (controlo), e foi posteriormente efetuada uma 
discussão comparativa dos danos toxicológicos desencadeados pelo tramadol e 
tapentadol. Após a realização de ensaios de SRB e MTT, observou-se que o tapentadol 
causou uma maior diminuição da biomassa, assim como da atividade metabólica. 
Contudo, ambos os opioides causaram toxicidade e diminuição da viabilidade celular, 
analisada através de ensaios de marcação ao azul de tripano. No que concerne ao 
aumento de stresse oxidativo, não se observaram alterações na peroxidação lipídica ou 
na oxidação proteica, após a exposição a tramadol ou tapentadol, pelo que a toxicidade 
resultante da exposição a estes opioides não deverá ser, predominantemente, uma 
consequência de danos oxidativos. Por outro lado, observou-se a existência de uma 
crise bioenergética caracterizada pelo aumento dos níveis intracelulares de glucose, 
aliado à diminuição dos níveis de ATP e aumento dos níveis de lactato, como resultado 
de alterações da expressão de genes que codificam enzimas do metabolismo energético 
(tais como: LDH (lactato desidrogenase), NDUFS1 (Fe-S proteína 1 do complexo 
NADH desidrogenase), CKB (creatina cinase B), PDK3 (piruvato desidrogenase cinase 
3) e ALDOC (aldolase C)). Neste contexto, os resultados obtidos permitiram concluir 
que, no modelo utilizado, o tapentadol causou uma maior toxicidade, promovendo uma 
crise bioenergética e uma maior morte celular, comparativamente ao tramadol. 
Verificou-se ainda que o principal mecanismo de morte, após a exposição a ambos os 
opioides, foi a necrose, não se tendo observado alterações no potencial de membrana 
mitocondrial, nem o aumento da libertação do citocromo c, assim como se observou 
apenas um ligeiro aumento na atividade das caspases. 
Após a conclusão dos ensaios in vitro, realizaram-se ensaios de exposição aguda 
in vivo, utilizando ratos Wistar machos. Os ensaios in vivo permitiram um estudo mais 
abrangente e completo do perfil toxicológico destes opioides. Nestes ensaios, 
administraram-se por via intraperitoneal doses de 10, 25 ou 50 mg/Kg de tramadol e 
tapentadol (preparadas em 1 ml de solução salina de NaCl a 0,9%), que correspondem, 
respetivamente, à dose analgésica frequentemente prescrita, uma dose intermédia, e à 
dose máxima diária recomendada. Um grupo de animais controlo foi incluído no estudo, 
ao qual se administrou, por via intraperitoneal, 1 mL de solução salina de NaCl a 0,9%. 
Vinte e quatro horas após a administração, avaliou-se a existência de alterações 
bioquímicas, assim como alterações histológicas e danos oxidativos nos tecidos 
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cerebral, pulmonar e cardíaco. No que concerne a alterações bioquímicas analisadas no 
soro, ambos os fármacos levaram a um aumento da razão AST/ALT (aspartato 
transaminase/alanina transaminase), assim como ao aumento da atividade das enzimas 
LDH (lactato desidrogenase), CK (creatina cinase) e CK-MB (creatina cinase-isoforma 
MB). Nos tecidos pulmonar e cardíaco, observou-se um aumento de oxidação proteica. 
Na análise histológica, no tecido cerebral observaram-se alterações, tais como a 
presença de neurónios inchados, células com membrana nuclear mal definida, assim 
como a presença de células mortas. No tecido pulmonar, verificou-se a presença de 
hemorragia intra-alveolar e colapso alveolar. Foi também observada toxicidade 
cardíaca, caracterizada pela presença de infiltrados inflamatórios e perda da estriação 
dos cardiomiócitos, que, em conjunto com as alterações bioquímicas observadas, 
permitiram concluir que estes opioides causam dano cardíaco. A análise combinada de 
todos os resultados obtidos in vivo permitiu concluir que o tratamento com tapentadol 
conduziu a efeitos mais tóxicos do que a exposição a tramadol.  
 Em conclusão, os resultados do presente trabalho demostraram que o tramadol 
e o tapentadol apresentam toxicidade, mesmo num cenário de exposição aguda, sendo 
o tapentadol mais tóxico nos modelos utilizados. Destaca-se ainda que os resultados 
obtidos constituem um importante ponto de partida que deve ser complementado com 
ensaios de exposição crónica a ambos os opioides, assim como com ensaios de 
exposição simultânea a outras drogas/fármacos. A compreensão das alterações 
moleculares e bioquímicas desencadeadas pelos opioides permitirá reconhecer e melhor 
explicar as reações adversas, e constitui uma ferramenta adicional para a avaliação de 
casos de intoxicação decorrentes da exposição a estes compostos.  
Neste contexto, os resultados obtidos sublinham a necessidade de uma prescrição 
cuidadosa e consciente de tramadol e tapentadol, devendo a escolha do opioide ser 
ponderada individualmente, de modo a otimizar estratégias terapêuticas e minimizar 
efeitos adversos. 
 
Palavras-chave: Ensaios de toxicidade, neurotoxicidade, pneumotoxicidade, 
cardiotoxicidade, exposição aguda, in vivo, in vitro, opioides, tapentadol, tramadol. 		
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Abstract
Moderate-to-severe pain represents a heavy burden in patients’ quality
of life, and ultimately in the society and in healthcare costs. The aim of
this review was to summarize data on tramadol and tapentadol adverse
effects, toxicity, potential advantages and limitations according to the
context of clinical use. We compared data on the pharmacological and
toxicological profiles of tramadol and tapentadol, after an extensive
literature search in the US National Library of Medicine (PubMed).
Tramadol is a prodrug that acts through noradrenaline and serotonin
reuptake inhibition, with a weak opioid component added by its
metabolite O-desmethyltramadol. Tapentadol does not require metabolic
activation and acts mainly through noradrenaline reuptake inhibition
and has a strong opioid activity. Such features confer tapentadol
potential advantages, namely lower serotonergic, dependence and abuse
potential, more linear pharmacokinetics, greater gastrointestinal
tolerability and applicability in the treatment of chronic and neuropathic
pain. Although more studies are needed to provide clear guidance on
the opioid of choice, tapentadol shows some advantages, as it does not
require CYP450 system activation and has minimal serotonergic effects.
In addition, it leads to less side effects and lower abuse liability.
However, in vivo and in vitro studies have shown that tramadol and
tapentadol cause similar toxicological damage. In this context, it is
important to underline that the choice of opioid should be individually
balanced and a tailored decision, based on previous experience and on
the patient’s profile, type of pain and context of treatment.
Significance: This review underlines the need for a careful prescription
of tramadol and tapentadol. Although both are widely prescribed
synthetic opioid analgesics, their toxic effects and potential dependence
are not completely understood yet. In particular, concerning tapentadol,
further research is needed to better assess its toxic effects.
1. Introduction
The use, misuse and abuse of analgesics have
increased throughout the last decades (Compton and
Volkow, 2006; Manchikanti et al., 2010; Compton
et al., 2015; Kaye et al., 2017). Prescription opioids,
the mainstay of chronic pain treatment, have largely
contributed to this phenomenon, leading to the so-
called opioid epidemic and a public health crisis asso-
ciated with an increase in the number of opioid-
related morbidity and mortality (Burgess and Wil-
liams, 2010; Manchikanti et al., 2010; Mercadante
© 2018 European Pain Federation - EFIC! Eur J Pain 22 (2018) 827--844 827
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et al., 2012; Meneghini et al., 2014; Compton et al.,
2015; Mercadante, 2015; Crow, 2016; Just et al.,
2016; Agarwal et al., 2017; Han et al., 2017; Pezalla
et al., 2017). Besides the typical unwanted side
effects caused by opioids, including bowel dysfunc-
tion and constipation, vomiting, nausea, itching, sex
hormone dysfunction (hypogonadism), somnolence,
sleep and concentration difficulties (which some-
times lead to treatment discontinuation), other
effects related to tolerance, dependence and addic-
tion potential, as well as possible fatal overdose, rep-
resent additional troubling concerns (Burgess and
Williams, 2010; Manchikanti et al., 2010; Mer-
cadante et al., 2012, 2014; Gunther et al., 2017;
Ventura et al., 2017). Therefore, the demand for the
development of new analgesic formulations with
nonexistent or reduced side effects and abuse poten-
tial has never been so urgent (Burgess and Williams,
2010; Crow, 2016; Gunther et al., 2017; Pezalla
et al., 2017; Vadivelu et al., 2017).
Tramadol and tapentadol are two centrally acting,
fully synthetic opioids with an atypical mechanism
of action, as they combine l-opioid receptor (MOR)
agonism with neurotransmitter (serotonin (5-HT)
and/or noradrenaline (NA) reuptake inhibition (Bar-
bosa et al., 2016). They are two synthetic and struc-
turally related opioids. Tramadol was first
synthetized in 1962, having then been tested for
15 years and made available to the foreign market,
for pain treatment, in 1977, under the name Tramal
(Grond and Sablotzki, 2004; Vadivelu et al., 2017).
However, it was not until 1994 and 1995 that it was
registered as a new molecular entity in the United
Kingdom and in the United States, respectively
(Grond and Sablotzki, 2004; Kissin, 2010). In turn,
tapentadol was developed in the late 1980s, aiming
at a new class of analgesics, retaining MOR agonism
and NA reuptake inhibition, while having minimal
5-HT effect (Knezevic et al., 2015; Langford et al.,
2016; Vadivelu et al., 2017). The tapentadol
hydrochloride immediate release (IR) formulation
obtained approval by the United States Food and
Drug Administration (FDA) in 2008, for the manage-
ment of moderate-to-severe acute pain, while an
extended release (ER) formulation was approved for
the treatment of moderate-to-severe chronic pain
and neuropathic pain in 2011 and 2012, respectively
(Mercadante et al., 2014; Knezevic et al., 2015;
Chang et al., 2016).
In spite of the partial share of mechanism of
action, tapentadol is, in some ways, regarded as an
upgrade over tramadol – the limitations of tramadol
have been used as a starting point for the
development of tapentadol. Nevertheless, there is
few information available on the comparison of their
adverse events and toxicological profiles, mainly due
to the more limited history of tapentadol in the mar-
ket. With this review, we aimed to summarize data
on tramadol and tapentadol opioid and nonopioid-
related adverse effects, toxicity, and potential advan-
tages and limitations according to the context of clin-
ical use.
2. Methodology
An extensive literature search was performed using
text and structural queries for tramadol, tapentadol
and data concerning their toxicity and abuse poten-
tial in the US National Library of Medicine
(PubMed), with no restriction of publication date or
language. The publications retrieved were addition-
ally screened as referrals to others. Bibliographical
references concerning in vitro and in vivo (human
and non-human) studies were considered.
3. Chemical remarks
Tramadol, (1RS, 2RS)-2-[(dimethylamino)methyl]-1-
(3-methoxyphenyl)-cyclo-hexanol, is a synthetic 4-
phenyl-piperidine; as codeine, it has a 3-methoxy
group substitution on the phenolic moiety (Fig. 1),
which explains the weak affinity for opioid receptors
(Dayer et al., 1994), and has O-demethylation as a
metabolic step, producing metabolites with higher
pharmacological activity (Grond and Sablotzki, 2004;
Raffa et al., 2012). The dimethylaminomethyl moi-
ety of tramadol resembles the methylated ring nitro-
gen of morphine and codeine, composing a
fundamental part of the pharmacophore that inter-
acts with the MOR and monoamine transporters
(Grond and Sablotzki, 2004; Raffa et al., 2012).
Tapentadol, 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-
2-methylpropyl]-phenol, was developed from the
structures of morphine, tramadol and its metabolite
O-desmethyltramadol (M1), in the search for an
active parental compound, composed of only one
enantiomer displaying both MOR and NA activities,
and devoid of cytochrome P450 (CYP450) metabo-
lism (Chang et al., 2016; Langford et al., 2016). This
led to the opening of tramadol cyclohexane ring and
to the replacement of the tertiary hydroxyl group
(Chang et al., 2016). The result is a meta-substituted
phenol ring with an ethyl and an aminopropyl resi-
due at C9, located in opposite sides of the plane
defined by the aromatic ring (Arjunan et al., 2015;
Knezevic et al., 2015; Chang et al., 2016). C8 and
828 Eur J Pain 22 (2018) 827--844 © 2018 European Pain Federation - EFIC!
Tramadol and tapentadol toxicity J. Faria et al.
  
____________________________________________________________Part I - General Introduction 
 7 
 
C9 are two stereogenic centres, leading to four possi-
ble diastereomers, from which the (R,R) isomer is
currently the used form in the clinics (Fig. 2) (Arju-
nan et al., 2015; Knezevic et al., 2015). Tapentadol
is structurally the closest chemical compound to tra-
madol in clinical use (Arjunan et al., 2015).
4. Formulations and pharmacokinetic
profile comparison
Tramadol is delivered through different routes of
administration (such as oral, intranasal, rectal and
intravenous), in IR and ER formulations (Grond and
Sablotzki, 2004). Oral formulations are the preferred
route used in the clinics (Leppert, 2009). Neverthe-
less, in severe pain, after surgery, intravenous for-
mulations represent a more appropriate option
(Grond and Sablotzki, 2004). In turn, tapentadol is
available in oral formulations only, both for IR and
ER (Tzschentke et al., 2007; Singh et al., 2013).
Following oral administration, tramadol is rapidly
and almost completely absorbed and distributed in
the body, with 20-30% undergoing first-pass meta-
bolism (Grond and Sablotzki, 2004). Its bioavailabil-
ity achieves 68–84%, while its plasma protein
binding is 20% (Grond and Sablotzki, 2004; Barbosa
TramadolMorphineCodeine
S,S-Tramadol R,R-Tramadol O-Desmethyltramadol N-Desmethyltramadol
A
B
O
O
HO
H
N
HO
O
HO
H
N
Figure 1 Molecular structures of codeine, morphine and tramadol with their common structure in red, and the dimethylaminomethyl moiety of
tramadol, a fundamental part of the pharmacophore, in blue (A). Molecular structures of both tramadol enantiomers and its main metabolites (B).
O-desmethyltramadol (M1) is produced via CYP2D6, while N-desmethyltramadol (M2) is produced via CYP2B6 and CYP3A4.
Tapentadol Tapentadol-O-glucuronide
*
*
N
O
HO
OH
OH
O
O
OH
Figure 2 Molecular structures of tapentadol and its main metabolite, tapentadol-O-glucuronide, produced via UGT1A9- and UGT2B7-mediated glu-
curonidation. C8 and C9, the two stereogenic centres, are evidenced with asterisks.
© 2018 European Pain Federation - EFIC! Eur J Pain 22 (2018) 827--844 829
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et al., 2016). It is extensively metabolized in the
liver, through six metabolic pathways, from which
O-demethylation, N-demethylation and cyclohexyl
oxidation are the major routes, resulting in 7 O-des-
methyl/N-desmethyl and hydroxycyclohexyl meta-
bolites (Grond and Sablotzki, 2004; DePriest et al.,
2015; Barbosa et al., 2016; Wu et al., 2017).
CYP450-mediated phase I reactions yield 14 metabo-
lites, from which M1 stands out for its prominent
pharmacological activity. CYP2D6 mediates M1 for-
mation, while CYP2B6 and CYP3A4 are responsible
for N-desmethyltramadol (M2) production (Grond
and Sablotzki, 2004; DePriest et al., 2015; Barbosa
et al., 2016; Wu et al., 2017). Phase II reactions pro-
duce 12 metabolites, including seven glucuronides
and five sulphonates (Grond and Sablotzki, 2004;
DePriest et al., 2015; Barbosa et al., 2016; Wu et al.,
2017). Tramadol elimination is mainly urinary
(90%), and the M1, M2, N,N-didesmethyltramadol
(M3), O,N,N-tridesmethyltramadol (M4) and O,N-
didesmethyltramadol (M5) metabolites are mostly
detected in urine upon oral administration (Grond
and Sablotzki, 2004; Wu et al., 2017).
In turn, tapentadol is a nonracemic molecule that
does not require metabolic activation via the CYP450
system (Bourland et al., 2010; Hartrick and Rozek,
2011; Barbosa et al., 2016). As for tramadol, its
absorption is fast and complete, undergoing first-pass
metabolism and plasma protein binding (20%), with
an estimated bioavailability of 32%, upon extensive
glucuronidation (Hartrick and Rozek, 2011). While
tapentadol is subject to phase I oxidative reactions
that include its N-demethylation (13%) via CYP2C9
and CYP2C19 and its hydroxylation (2%) via
CYP2D6, its metabolism mainly comprises phase II
glucuronidations (55%) via UGT1A9 and UGT2B7,
as well as sulphonations (15%) (Kneip et al., 2008;
Bourland et al., 2010; Coulter et al., 2010; Hartrick
and Rozek, 2011; Kemp et al., 2013; Singh et al.,
2013; DePriest et al., 2015; Barbosa et al., 2016;
Bairam et al., 2017). Elimination occurs mainly
through the kidney (99%) (Hartrick and Rozek,
2011).
CYP2D6 is a polymorphic enzyme; due to the con-
siderable dependence of tramadol pharmacological
activity on the bioactivation by CYP2D6, and consid-
ering the genetic variability affecting this enzyme, it
becomes clear that tramadol pharmacokinetics is
highly dependent on the individual genotype.
Indeed, CYP2D6 ultra-rapid metabolizers (UMs) have
an increased risk of side effects, with this phenotype
having been associated with cases of toxicity. On the
other hand, the CYP2D6 poor metabolizer (PM)
phenotype was associated with less tramadol anal-
gesic efficacy, with lower M1 concentrations and
increased tramadol half-life (Poulsen et al., 1996;
Lassen et al., 2015; Barbosa et al., 2016). This is par-
ticularly relevant considering that the frequency of
PMs is 7-10% in Caucasians, 2–7% in Hispanics, 0-
5% in Asia (0–5%) and more variable in the African
population (0–19%), depending on the region (Las-
sen et al., 2015). Concerning the frequency of UMs,
the highest values are in Black Ethiopians (16%)
and Saudi Arabians (20%), while the lowest values
are among North Europeans (0.8–3.6%) and Ameri-
can Caucasians and Blacks (4.3 and 4.5%, respec-
tively); the frequency in Mediterranean Europeans
corresponds to 7–10% (Lassen et al., 2015). In con-
trast, for UGT2B7, no polymorphisms have been
reported as clinically relevant, and this is not a very
polymorphic enzyme (Lassen et al., 2015).
Tramadol and tapentadol metabolic pathways have
been extensively reviewed elsewhere (Barbosa et al.,
2016). A comparative summary of relevant features
of the pharmacokinetics of both drugs is provided in
Table 1.
5. Pharmacodynamic profile comparison
Besides enhancing their analgesic effects, tramadol
and tapentadol dual mechanism of action signifi-
cantly increases tolerability and reduces the adverse
effects associated with classical opioids.
Tramadol is marketed as a racemate composed of
(+)-tramadol and (!)-tramadol. While (!)-tramadol
is mostly responsible for the inhibition of NA reup-
take, (+)-tramadol is more potent in the inhibition of
5-HT reuptake (Duthie, 1998; Grond and Sablotzki,
2004; Leppert, 2011; Barbosa et al., 2016) (Fig. 3). In
turn, MOR agonism is mainly ensured by the (+)-
enantiomer of the M1 metabolite and, to a lesser
extent, by the parental compound ((+)-tramadol) (Lai
et al., 1996; Duthie, 1998; Gillen et al., 2000; Grond
and Sablotzki, 2004; Leppert, 2011; Barbosa et al.,
2016). The (!)-M1 enantiomer is responsible for NA
reuptake inhibition (Duthie, 1998; Grond and
Sablotzki, 2004; Leppert, 2011; Barbosa et al., 2016).
Tapentadol shows moderate MOR agonist activity,
pronounced NA reuptake inhibition and minimal 5-
HT effect (Table 2) (Tzschentke et al., 2007; Hartrick
and Rozek, 2011; Meske et al., 2014; Barbosa et al.,
2016), thereby minimizing the risk of serotonin syn-
drome (Tzschentke et al., 2007; Hartrick and Rozek,
2011; Giorgi et al., 2012; Steigerwald et al., 2013;
Meske et al., 2014; Barbosa et al., 2016). NA inhibits
the transmission of nociceptive impulses by
830 Eur J Pain 22 (2018) 827--844 © 2018 European Pain Federation - EFIC!
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activating a2-adrenergic receptors on pain fibres in
the Central Nervous System (CNS). By blocking NA
reuptake, tapentadol thus prolongs its effects at the
terminal endings of interneurons and descending
inhibitory fibres, suppressing pain transmission (Vadi-
velu et al., 2017) (Fig. 4). Combined with its MOR
agonism, which is associated with the modulation of
ascending pathways, these complementary effects
lead to a high level of analgesia, compensating the
lower MOR binding affinity (Knezevic et al., 2015;
Chang et al., 2016; Vadivelu et al., 2017). In fact, the
synergistic effect of both mechanisms of action
explains why tapentadol is only about threefold less
potent than morphine, although its MOR affinity is
18-fold lower (Knezevic et al., 2015; Chang et al.,
2016; Vadivelu et al., 2017). Table 2 comparatively
lists some important pharmacodynamic features of
both opioids.
Table 1 Comparative summary of main tramadol and tapentadol pharmacokinetic aspects (Dayer et al., 1994, 1997; Matthiesen et al., 1998; Wade
and Spruill, 2009; Singh et al., 2013; Mercadante et al., 2014; Arjunan et al., 2015; Knezevic et al., 2015; McNaughton et al., 2015; Barbosa et al.,
2016; Chang et al., 2016; Langford et al., 2016; Agarwal et al., 2017; Pergolizzi et al., 2017; Vadivelu et al., 2017; Wu et al., 2017).
Tramadol Tapentadol
Route(s) of administration/doses • Oral IR: 50 mg tablets/capsules; 37.5 mg tra-
madol + 325 mg acetaminophen tablets/capsules
• Oral ER: 50, 100, 150, 200, 300 mg tablets/cap-
sules
• Intramuscular: 50 mg/mL suspension
• Rectal IR: 100 mg suppositories
• Oral IR: 50, 75, 100 mg tablets
• Oral ER: 50, 100, 150, 200, 250 mg tablets
Recommended daily dose (mg) 100–300 50–100
Maximum daily dose (mg) 400 600–700
Absorption Intestinal Intestinal
Onset of action for IR formulations 60 min 30 min
Plasma peak • Oral, IR: 1–2 h (racemic tramadol); 3 h (M1)
• Oral, ER: 4.9 h
• Intramuscular: 30–45 minutes
• Rectal: 3 h
• Oral, IR: 1–1.5 h
• Oral, ER: 3–6 h
Metabolism • Hepatic
• Main reactions: Phase I CYP2D6-mediated O-
demethylation to M1
• Minor reactions: CYP2B6- and CYP3A4-mediated
N-demethylation to M2
• Hepatic
• Main reactions: Phase II glucuronidation reactions,
through UGT1A9 and UGT2B7, to tapentadol-O-glu-
curonide (55%)
• Minor reactions: CYP2D6-mediated oxidation to
hydroxytapentadol (2%), CYP2C9- and CYP2C19-
mediated oxidation to N-desmethyltapentadol (13%)
Main metabolites • M1
• M2
Tapentadol-O-glucuronide
Active metabolite M1 Active parental compound
Bioavailability 68–84% 32%
Plasma protein binding 20% 20%
Elimination half-life • 5–6 h (racemic tramadol)
• 8–9 h (M1)
• ~4 h for IR formulations
• 5–6 h for ER formulations
Excretion • Renal (90%): M1 (16%); M5 (15%); M2 (2%);
metabolite conjugates; unchanged tramadol (10–
30%)
• Faecal (10%)
• Renal (99%): conjugated (glucuronide, sulphate) form
(69%); other metabolites (27%); unchanged tapentadol
(3%)
• Faecal (1%)
Drug–drug interactions CYP2D6-mediated metabolism increases
susceptibility to drug interactions
Absence of significant CYP450-mediated metabolism
decreases liability to drug interactions
Interindividual variability CYP450 genetic polymorphisms determine different
metabolizer phenotypes and, thus, analgesic
efficacy
No evidences of polymorphisms significantly affecting
metabolism and analgesic efficacy
M1, O-desmethyltramadol; M2, N-desmethyltramadol; IR, immediate release; ER, immediate release; CYP450, cytochrome P450; UGT, UDP-glucuro-
nosyltransferase.
© 2018 European Pain Federation - EFIC! Eur J Pain 22 (2018) 827--844 831
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6. Clinical applications and efficacy
Tramadol and tapentadol provide an opiate-sparing
effect through their atypical and dual mechanism of
action, which is an advantage over classical opioids,
particularly in chronic treatment, where opioid
receptor downregulation takes place (Giorgi, 2012).
As such, given the duality and synergy of their
mechanisms of action (Grond and Sablotzki, 2004;
Tzschentke et al., 2007) and the resulting fewer side
effects and lower addiction potential, tramadol and
tapentadol are typically recommended for the treat-
ment of moderate to severe pain. Table 3 illustrates
main tramadol and tapentadol clinical applications
(Dayer et al., 1994, 1997; Matthiesen et al., 1998;
Wade and Spruill, 2009; Singh et al., 2013; Mer-
cadante et al., 2014; Arjunan et al., 2015; Knezevic
et al., 2015; McNaughton et al., 2015; Barbosa et al.,
2016; Chang et al., 2016; Langford et al., 2016;
Agarwal et al., 2017; Pergolizzi et al., 2017; Vadivelu
et al., 2017; Wu et al., 2017).
The analgesic efficacy of tramadol has been veri-
fied in the treatment of acute and chronic situations.
It is usually used in cancer pain. For instance, Grond
and colleagues have verified the clinical efficacy of
tramadol in the treatment of moderate oncological
pain, when nonopioids fail to be effective (Grond
et al., 1999). Nonetheless, it is also used in nonma-
lignant pain, such as in osteoarthritis pain (Grond
and Sablotzki, 2004; Leppert, 2009). Cepeda and co-
authors, in a meta-analysis, reported less adverse
effects for osteoarthritic pain patients receiving tra-
madol or tramadol/paracetamol compared to partici-
pants who received placebo (Cepeda et al., 2007).
Several randomized, double-blind studies evaluating
Pain message
Pain 
transmi!er
Ascending pathway
to the brain
NA
Tramadol
5-HT
MOR
α2-AR
Descending pathway
from the brain
Reuptake 
transporter protein
Figure 3 Tramadol dual mechanism of action. Tramadol acts through l-opioid receptor (MOR) agonism, and both NA and 5-HT reuptake inhibition.
NA and 5-HT inhibit the transmission of nociceptive impulses by activating a2-adrenergic receptors. Pain neurotransmitters glutamate and sub-
stance P bind the respective receptors, modulating primary afferent pathways of pain stimulation. NA: noradrenaline; 5-HT: serotonin; MOR: l-
opioid receptor; a2-AR: a2-adrenergic receptor.
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the efficacy of tramadol and comparator drugs in post-
operative situations, such as those following ortho-
pedic, abdominal and gynaecological laparoscopic
surgery, have clearly evidenced the clinical efficacy of
tramadol (Grond and Sablotzki, 2004; Leppert, 2009).
In some nociceptive and neuropathic pain situa-
tions, tramadol is a good approach for moderate pain
treatment (Sindrup et al., 1999a,b; Leppert, 2009).
However, concerning neuropathic pain, Duehmke
et al. (2017) underline the lack of information about
tramadol use in this context, in addition to the inade-
quate studies available. These authors suggested a bias
towards the increase in apparent tramadol benefits, so
the conclusions may not reliably reflect the real sce-
nario (Duehmke et al., 2017). A systematic review
and meta-analysis by Finnerup et al. (2015), concern-
ing neuropathic pain treatment in adults from Jan-
uary 1966 to April 2013, reported tramadol and
tapentadol number needed to treat as 4.7 and 10.2,
respectively. The combination between tramadol and
nonopioid drugs, such as paracetamol, dipyrone and
ketorolac, increases analgesia without increasing the
risk of serious adverse events (Grond and Sablotzki,
2004; Leppert, 2009; Sawaddiruk, 2011). However, it
is imperative to monitor tramadol analgesic efficacy
and its potential adverse effects; in this context, the
titration of tramadol dose is of particular importance
(Grond and Sablotzki, 2004; Leppert, 2009).
Tapentadol ER showed to be safe for patients with
hypertension, a frequent condition in subjects with
chronic pain. In this situation, no significant changes
in heart rate or blood pressure were detected (Biondi
et al., 2014), a clinical condition for which tapenta-
dol is a possible option for pain treatment, in opposi-
tion to paracetamol, NSAIDs and COX-2 inhibitors,
which have been associated with increases in blood
pressure (Schnitzer, 2006; Sudano et al., 2010;
Snowden and Nelson, 2011; Biondi et al., 2014).
Serotonin-noradrenaline reuptake inhibitors (SNRIs)
are also associated with hypertension (Stahl et al.,
2005; Biondi et al., 2014), for which tapentadol is
suggested to present increased cardiovascular safety,
and to be a better option than tramadol in such situ-
ations. Tapentadol IR formulations were also shown
to be better than similar oxycodone forms in the
treatment of postsurgical pain, as they were associ-
ated with lower rates of gastrointestinal adverse
events and higher cost savings in postsurgical hospi-
tal settings (Paris et al., 2013; Mercadante et al.,
2014). In a review by Candiotti and Gitlin, tapenta-
dol therapy was also reported to show an improved
gastrointestinal tolerability profile, with low inci-
dence of constipation (7% and 10%, in the treat-
ment with tapentadol ER 100 mg and 200 mg,
respectively) (Candiotti and Gitlin, 2010). However,
other studies suggest that acute administration of
tapentadol may not have significant advantages in
gastrointestinal motor dysfunction, delaying gastric
and small bowel transit, similarly to oxycodone
(Jeong et al., 2012). In turn, a network meta-
Table 2 Comparative summary of main tramadol and tapentadol pharmacodynamic aspects (Dayer et al., 1994, 1997; Matthiesen et al., 1998;
Wade and Spruill, 2009; Raffa et al., 2012; Singh et al., 2013; Mercadante et al., 2014; Arjunan et al., 2015; Knezevic et al., 2015; McNaughton
et al., 2015; Barbosa et al., 2016; Chang et al., 2016; Langford et al., 2016; Agarwal et al., 2017; Pergolizzi et al., 2017; Vadivelu et al., 2017; Wu
et al., 2017).
Class
Tramadol Tapentadol
Opioid agonist Opioid agonist
Mechanism of action • MOR agonism ((+)-M1)
• 5-HT reuptake inhibition ((+)-tramadol)
• NA reuptake inhibition ((!)-tramadol)
• MOR agonism
• Strong NA reuptake inhibition
• Weak 5-HT reuptake inhibition
MOR binding affinity (compared to that of morphine) Weak (1/6000) Strong (1/18)
MOR Ki binding affinity (lM) • Racemic tramadol = 2.4
• (+) Tramadol = 1.3
• (!) Tramadol = 24.8
• (+) M1 = 0.0034
• (!) M1 = 0.24
0.16
NA transporter Ki binding affinity (lM) Racemic tramadol = 14.6 8.8
5-HT transporter Ki binding affinity (lM) Racemic tramadol = 1.19
(+) Tramadol = 0.87
5.28
Practical equianalgesic dose to 10 mg morphine (mg) 50 25
Equianalgesic dose conversion factor (opioid dose "
factor = morphine dose)
"5 "2.5
M1, O-desmethyltramadol; MOR, l-opioid receptor; 5-HT, serotonin; NA, noradrenaline.
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analysis of randomized-controlled trials showed
tapentadol to have the best tolerability profile when
compared to oxycodone-naloxone, tramadol, oxy-
codone, fentanyl, morphine, hydromorphone,
buprenorphine and oxymorphone, as it leads to the
lowest rates of adverse events, constipation and trial
withdrawal, ranking third for the ‘patient satisfac-
tion’ criteria only (Meng et al., 2017). In a prospec-
tive open-label study on tapentadol efficacy and
tolerability in patients with moderate-to-severe can-
cer pain, pain intensity significantly decreased from
baseline, with quality of life improvement and no
changes in adverse effects; the tendency to increase
the dose was low and independent of sex, age and
pain mechanism (Mercadante et al., 2012). Nonethe-
less, the number of enrolled patients was low and
further, larger studies are required (Mercadante
et al., 2012). Moreover, tapentadol might be useful
for its antihyperalgesic effects, such as those
observed in hyperexcitation states of patients under-
going consecutive unsuccessful opioid trials (Schro-
der et al., 2010). Importantly, in vitro and in vivo
studies showed that tapentadol causes lower inhibi-
tion of hippocampal neurogenesis than morphine, as
well as other classical opioids, arising as an attractive
alternative for the treatment of neuropathic pain
(Meneghini et al., 2014), which has a particularly
complex pathophysiology (Burgess and Williams,
2010). Tapentadol noradrenergic component has
been suggested to potentially counteract the negative
MOR-mediated effects on hippocampal neurogenesis,
with its antiapoptotic and proneurogenic effects
being mediated by adrenergic receptors (Meneghini
et al., 2014; Bortolotto and Grilli, 2017). The
increasing role of the noradrenergic component
observed over time in persistent neuropathic pain
models further reinforces tapentadol suitability for
the treatment of neuropathic pain (Langford et al.,
Pain message
Pain 
transmi!er
Ascending pathway
to the brain
MOR
Reuptake 
transporter protein
α2-AR
Descending pathway
from the brain
Tapentadol
NA
Figure 4 Tapentadol dual mechanism of action. Tapentadol acts through l-opioid receptor (MOR) agonism and NA reuptake inhibition. NA inhibits
the transmission of nociceptive impulses by activating a2-adrenergic receptors. Pain neurotransmitters glutamate and substance P bind the respective
receptors, modulating primary afferent pathways of pain stimulation. NA: noradrenaline; MOR: l-opioid receptor; a2-AR: a2-adrenergic receptor.
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2016). Owing to the combination of two modes of
action, tapentadol also seems to be a good option for
the treatment of mixed pain, as nociceptive and neu-
ropathic pain arise from different pathogenic mecha-
nisms (Borsook et al., 2014; Coluzzi et al., 2017).
Moreover, considering the functional and structural
neuroplasticity changes and pain modification path-
ways that accompany pain chronification, tapentadol
emerges as a promising therapeutic alternative for
chronic pain (Borsook et al., 2014; Coluzzi et al.,
2017).
6.1 Paediatric use
In this context, an important point is the paediatric
use of tramadol and tapentadol and their safety. Tsu-
taoka et al. also compared the use of tramadol and
tapentadol in children aged <6 years old, with tapen-
tadol showing a significantly higher risk for severe
outcomes, and this higher risk was suggested as a
consequence of tapentadol having a higher MOR
binding affinity than tramadol. However, in this
study, the number of children exposed to tapentadol
(groups <6 years, 6 to 12 years and 13 to 19 years)
was substantially lower than that of children
exposed to tramadol (Tsutaoka et al., 2015), thereby
limiting the comparative analysis and the conclu-
sions on tapentadol toxic effects. However, Borys
et al. studied tapentadol toxicity in 104 children,
from which 62 had no effects, 34 had minor, six had
moderate and two had major effects with life-threa-
tening events (Borys et al., 2015). In this study, the
side effects reported were similar to other opioid
analgesics, including drowsiness, lethargy, nausea,
vomiting, miosis, tachycardia, respiratory depression,
dizziness/vertigo, coma, dyspnoea, pallor, oedema,
hives/welts, slurred speech, pruritus and hallucina-
tions/delusions (Borys et al., 2015).
To evaluate tramadol toxicity in children, a retro-
spective assessment of 7334 cases, of children aged
<6 years and tramadol acute ingestion only, was per-
formed (Stassinos et al., 2017). Only one death was
observed, while in most of the children, no effects
were observed (84.8%); minor effects were observed
Table 3 Comparative summary of main tramadol and tapentadol clinical and toxicological aspects (Dayer et al., 1994, 1997; Matthiesen et al.,
1998; Wade and Spruill, 2009; Singh et al., 2013; Mercadante et al., 2014; Arjunan et al., 2015; Knezevic et al., 2015; McNaughton et al., 2015;
Barbosa et al., 2016; Chang et al., 2016; Langford et al., 2016; Agarwal et al., 2017; Pergolizzi et al., 2017; Vadivelu et al., 2017; Wu et al., 2017).
Tramadol Tapentadol
Main indications Acute and chronic, moderate to severe forms of:
• Postoperative pain
• Odontological pain
• Cancer pain
• Musculoskeletal pain
• Adjuvant to NSAID therapy in osteoarthritis
Acute and chronic, moderate to severe forms of:
• Postoperative pain
• Musculoskeletal pain
• Neuropathic pain (e.g. associated with diabetic
peripheral neuropathy)
• Mixed pain states
Main contraindications • Concomitant use of MAOIs and/or tricyclic
antidepressants
• Renal and/or hepatic failure
• Pregnancy
• Lactation
• CYP2D6-defective subjects
• Impaired pulmonary function
• Paralytic ileus
• Concomitant use, within a 14 day-window, of MAOIs
• Safety in pregnancy, lactation, children < 18 years
old, hepatic and renal commitment has not been
fully established
Main complications • Serotonin syndrome
• Respiratory depression
• Seizures
• Nausea and vomiting
• Dizziness
• Drowsiness
• Fatigue
• Increased sweating
• Constipation
• Respiratory depression
• Coma
• Nausea and vomiting
• Dizziness
• Lethargy and somnolence
Median lethal dose
(LD50, rat, oral) (mg/kg)
300 980
NSAIDs, nonsteroidal anti-inflammatory drugs; MAOIs, monoamine oxidase inhibitors.
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in 12.6% of the sample, moderate in 2.2% and
major in 0.4% only (Stassinos et al., 2017). The
most frequent symptoms were drowsiness and vom-
iting, and the most severe were respiratory depres-
sion, detected in 36 children exposed to 225 mg
tramadol median dose (minimum dose 7.9 mg/kg),
and seizures, observed in 24 children exposed to
525 mg tramadol median dose (minimum dose
4.8 mg/kg), but these effects were rarely detected
(Stassinos et al., 2017). In turn, Friedrichsdorf et al.
studied the efficacy and side effects of tramadol com-
pared to codeine/paracetamol, in 84 children aged
4–15 years, after tonsillectomy, concluding that both
treatments were efficient in pain management, with
no significant differences (Friedrichsdorf et al.,
2015). These authors defend tramadol use in chil-
dren in postoperative settings due to its good safety
profile and low potential for side effects (Friedrichs-
dorf et al., 2015). In this study, codeine/paracetamol
caused more oversedation, while tramadol treatment
caused more itching in the postoperative period
(Friedrichsdorf et al., 2015). In another study,
Bedirli et al. evaluated tramadol and fentanyl effi-
cacy and safety in children during upper gastroin-
testinal endoscopy. Tramadol led to a lower
frequency of adverse effects, a shorter recovery time,
and better hemodynamic and respiratory stability.
Accordingly, this study suggests that tramadol pro-
vides sedation as efficiently as fentanyl, but with
better safety and tolerance (Bedirli et al., 2012).
Although oral and intravenous tramadol formula-
tions are effective and well tolerated in children with
postoperative pain (Grond and Sablotzki, 2004),
more studies are needed to ascertain its efficacy. In
fact, it should be interpreted with caution, as there
are few studies available and some methodological
problems may be present, such as the use of differ-
ent validated and nonvalidated pain scales, with dif-
ferent pain triggers (Schnabel et al., 2015).
Moreover, it should be emphasized that the expo-
sure to tramadol and tapentadol by children aged
<6 years old was mainly unintentional, and that
dose data for the same responses were not confirmed
in laboratory assays (Borys et al., 2015; Tsutaoka
et al., 2015; Stassinos et al., 2017). More studies are
required to establish safety, clinical effects and toxic
ranges in paediatric patients, as well as to assess
potential differences between IR and ER forms.
6.2 Veterinary use
Concerning veterinary use, tramadol and tapentadol
clinical efficacy is uncertain and controversial, but
tapentadol appears as more promising because it is a
single and active enantiomer, has linear kinetics,
with no CYP450 induction/inhibition and showing
negligible 5-HT reuptake inhibition (Giorgi, 2012). In
fact, in a study developed by K€ogel et al., the acute
treatment with tramadol, morphine and tapentadol
in Beagle dogs was compared, showing that, in this
experimental model, tramadol did not promote
antinociception, in contrast to tapentadol or mor-
phine (Kogel et al., 2014). Lower M1 concentrations
were detected, suggesting decreased tramadol meta-
bolism, and explaining the absence of tramadol
antinociception (Kogel et al., 2014). Hence, in these
animals, treatment with tapentadol arises as a better
option (Kogel et al., 2014). However, in cats with
osteoarthritis, tramadol showed to be safe and effi-
cient, with the most common adverse events being
mydriasis, euphoria and sedation (Monteiro et al.,
2017). Thus, tramadol may be a good approach for
osteoarthritic treatment in cats (Monteiro et al.,
2017). Additionally, in this model, tapentadol shows
some disadvantages, such as a higher bioavailability
due to the defective glucuronidation observed in cats,
and a very low oral bioavailability (Giorgi, 2012). In
dogs, tapentadol showed to be rapidly absorbed after
oral administration, although with a low bioavailabil-
ity (4.4%); dose-dependent adverse effects, such as
salivation and sedation, were detected mostly after
intravenous administration (Giorgi et al., 2012).
Tapentadol effects were also assessed in goats after
intravenous and intramuscular administration, and
comprised tremors, ataxia, and severe hair loss 3 days
after administration (Lavy et al., 2014). Tapentadol
absorption was fast and with a short half-life
(1.29 h), after intramuscular injections, which also
led to a quite high bioavailability (Lavy et al., 2014).
However, more studies are required to evaluate tra-
madol and tapentadol safety in veterinary medicine.
7. Toxicity
In parallel with tramadol and tapentadol extensive
prescription and widely recognized efficacy in pain
treatment, several cases of toxicity, as well as death,
have been reported. In this context, some studies
were performed after tramadol or tapentadol expo-
sure. In humans, after oral administration of a single
dose of 100 mg, tramadol and tapentadol therapeutic
blood concentrations in adults are approximately
300 lg/L and 2.45 lg-eq/mL, respectively (Grond
and Sablotzki, 2004; Terlinden et al., 2007).
Symptoms of tramadol intoxication typically start
4 hours after administration, being reported for
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doses above 500 mg (Spiller et al., 1997). For higher
doses (>800 mg), the risk of coma and respiratory
depression is increased (Spiller et al., 1997), and fur-
ther accentuated when tramadol is taken in combi-
nation with other psychoactive substances, such as
ethanol and CNS depressants. Tramadol side effects
are varied; however, the most common events are
nausea, followed by vertigo, dizziness, vomiting,
tiredness, constipation, sweating, dry mouth and
sedation (Grond and Sablotzki, 2004; Shadnia et al.,
2008; Beakley et al., 2015) (Table 3). Other side
effects, also reported to be secondary to tramadol
exposure, include angioedema, exacerbated anticoag-
ulant effect, serotonin syndrome, CNS depression,
seizures and tachycardia (Beakley et al., 2015).
Another tramadol side effect is delayed ejaculation;
however, the mechanisms involved are not clearly
identified yet (Abdel-Hamid et al., 2016). Nonethe-
less, the long-term action on the monoaminergic sys-
tem has been suggested as a cause for sexual
dysfunction (Barber, 2011). In such situation, the
prolonged action on the monoaminergic system is
the possible cause of side effects involving sexual
dysfunction and weight increase (Barber, 2011). Tra-
madol efficacy is dependent on its metabolism,
through CYP450, to M1, which is 200-300 times
more potent than the parental compound in MOR
activation. Therefore, its effectiveness differs among
different subjects (Giorgi, 2012). In this context, the
genetic variability contributes to the susceptibility to
serotonin syndrome (Beakley et al., 2015) and
should be considered in a toxicological context. In
PMs, with lower CYP2D6 activity, (+)-tramadol
levels increase (Raffa, 2008; Barbosa et al., 2016),
thereby promoting serotonin reuptake inhibition and
increasing the risk of serotoninergic syndrome
(Grond and Sablotzki, 2004; Beakley et al., 2015).
On the other hand, in UM subjects with higher
CYP2D6 activity, an increase in M1 levels can lead
to more side effects, such as respiratory depression
(Stamer et al., 2008; Orliaguet et al., 2015), in par-
ticular in renal insufficiency patients who exhibit a
decrease in renal clearance, which contributes to
increased toxicity (Stamer et al., 2008). In this con-
text, a higher frequency of UMs in Southern Euro-
peans and Northern Africans may increase tramadol
adverse effects (Kirchheiner et al., 2008). Serotonin
syndrome is particularly important when patients
are being treated with multiple drugs that collec-
tively increase serotonin levels, such as selective
serotonin reuptake inhibitors (SSRIs), monoamine
oxidase inhibitors (MAOIs) and tricyclic antidepres-
sants (TCAs) (Goeringer et al., 1997; Sansone and
Sansone, 2009), which considerably increase the
potential for side effects and drug interactions (Beak-
ley et al., 2015).
Several studies with animal models documented
tramadol-induced toxicity in different organs, such
as liver, kidney, brain, heart and lung (Atici et al.,
2005; Samaka et al., 2012; Ezzeldin et al., 2014;
Ghoneim et al., 2014; Saleem et al., 2014; Awadalla
and Salah-Eldin, 2016; Barbosa et al., 2017; Faria
et al., 2017). Tramadol toxicity was observed
through biochemical and histological analyses. Sev-
eral alterations were detected, such as increased
aminotransferase activity, creatinine and blood urea
nitrogen (BUN) (Atici et al., 2005; Saleem et al.,
2014; Barbosa et al., 2017; Faria et al., 2017);
increased oxidative stress markers (e.g. malondialde-
hyde levels and decreased antioxidant activity)
(Ghoneim et al., 2014; Awadalla and Salah-Eldin,
2016; Barbosa et al., 2017; Faria et al., 2017) and
histopathological alterations (e.g. necrosis, vacuoliza-
tion, mononuclear cell infiltration) (Atici et al.,
2005; Samaka et al., 2012; El Fatoh et al., 2014;
Ezzeldin et al., 2014; Ghoneim et al., 2014; Saleem
et al., 2014; Awadalla and Salah-Eldin, 2016; Bar-
bosa et al., 2017; Faria et al., 2017). One study, con-
cerning human exposure, reports the case of a 19-
year-old male patient with a history of tramadol
abuse for 6 months, who was found unconscious
with multiple organ dysfunction syndrome. In this
situation, toxicological analyses only detected toxic
tramadol levels (blood concentration of 9.5 mg/L),
and medical analyses described several alterations,
comprising deep coma, acute respiratory distress syn-
drome, electrocardiogram with sinus tachycardia, as
well as hepatic, cardiac and renal dysfunction (Wang
et al., 2009), in accordance with nonclinical in vitro
and in vivo acute exposure studies (Faria et al., 2016,
2017; Barbosa et al., 2017). Hepatic dysfunction was
characterized by increased alanine and aspartate
aminotransferase activities and BUN levels (Wang
et al., 2009). Lung X-rays analysis showed diffuse
bilateral alveolar opacities, compatible with pul-
monary oedema (Wang et al., 2009). Acute liver fail-
ure, as well as nonfatal hepatobiliary dysfunction,
has also been reported for tramadol (Loughrey et al.,
2003; Randall and Crane, 2014). Similarly, myocar-
dial damage is reported as an autopsy finding in a
death caused by tramadol (Mannocchi et al., 2013),
as well as increased creatine kinase (CK) and CK-
MB activities (Wang et al., 2009). In this context,
tramadol treatment, when performed after surgical
coronary revascularization, was reported to aggra-
vate myocardial injury (Wagner et al., 2010).
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Nephrotoxicity has been also implied in tramadol
intoxications, as an increase in creatinine, BUN and
potassium levels were observed (Wang et al., 2009).
The most common side effects of tapentadol com-
prise nausea, vomiting, dizziness, headache and som-
nolence (Table 3). The incidence of constipation is
lower upon treatment with tapentadol than with
other opioids, which decreases the rates of treatment
discontinuation (Hartrick and Rozek, 2011). Given
that tapentadol presents considerably higher opioid
receptor activation, it may imply lower toxicity.
Additionally, as already mentioned, tapentadol has a
minimal serotonin effect, lowering the potential for
serotonin syndrome induction (Barbosa et al., 2016).
Regarding human studies, Kemp et al. reported a
death after tapentadol intravenous injection, with
tapentadol concentrations reaching 1.05 and
3.20 mg/L in femoral and heart blood, respectively
(Kemp et al., 2013). Larson and co-authors also
reported two deaths following tapentadol exposure,
with drug concentrations of 0.77 mg/L in femoral
blood and 1.65 mg/kg in the liver, in one of the
cases, and 0.26 mg/L in femoral blood and 0.52 mg/
kg in the liver, in the other case (Larson et al.,
2012). Besides these findings, foam cone was
observed in the nose and mouth, and pulmonary
congestion was detected in an autopsy context, for
which tapentadol might be regarded as a possible
lung damage-triggering factor (Kemp et al., 2013;
Faria et al., 2017). Pulmonary alterations (namely
pulmonary oedema) were also reported in a case of
tapentadol and oxycodone intoxication, where
tapentadol concentrations reached 1.1 mg/L in
peripheral blood, 1.3 mg/L in central blood, 9.9 mg/
kg in the liver, 0.94 mg/L in vitreous humour, and
88 mg/L in urine (Cantrell et al., 2016). Another
fatal intoxication by tapentadol was reported by
Franco et al., who suggested its acute ingestion; the
events responsible for death included respiratory and
CNS depression and serotonin syndrome, with
tapentadol concentration in cardiac blood being as
high as 6600 ng/mL, more than 20 times the higher
limit of its therapeutic range (Franco et al., 2014).
These authors also reported autolytic changes in kid-
ney, suggestive of tapentadol nephrotoxicity (Franco
et al., 2014).
Fewer studies have been performed concerning
tramadol and tapentadol comparative toxicity. In the
sequence of a comparative study of tramadol and
tapentadol toxicity in Wistar rats, Faria et al. (Faria
et al., 2017) concluded that both opioids cause brain,
pulmonary and cardiac toxic damage following a sin-
gle exposure, at typical effective doses, intermediate
doses and maximum recommended daily doses, with
tapentadol causing comparatively more toxic dam-
age. Following the same experimental approach,
Barbosa and co-workers reported tramadol and
tapentadol to lead to hepatotoxicity and nephrotoxi-
city, with the latter inducing more toxic damage
(Barbosa et al., 2017). In a study by Tsutaoka et al.
(Tsutaoka et al., 2015), the authors have compared
several cases, at different ages, of tapentadol or tra-
madol single medication. While tapentadol elicited
more toxic clinical effects and more severe outcomes
(namely greater risk of respiratory depression, coma,
drowsiness/lethargy and hallucinations), tramadol
caused more seizures and vomiting events. The
causes of seizures, after tramadol exposure, are
unclear, although some studies, using different mod-
els, have associated tramadol antidepressant activity
with seizures (Reeves and Cox, 2008; Reichert et al.,
2014). Besides the adverse reactions discussed so far,
more severe toxicological effects, with even more
serious implications, have been reported, including
respiratory depression, serotonin syndrome (Sansone
and Sansone, 2009; Pilgrim et al., 2011; Beakley
et al., 2015) and fatal intoxications (Tjaderborn
et al., 2007; Pilgrim et al., 2011; Larson et al., 2012;
Costa et al., 2013; Kemp et al., 2013; Pinho et al.,
2013; Franco et al., 2014; Cantrell et al., 2016).
Considering the number and the diversity of the
above-mentioned studies, it becomes clear that the
comparison between both drugs is far from being
straightforward. Given that tapentadol is a more
recently marketed drug, the number of studies
reporting its toxic effects is more limited, which
makes direct comparisons with tramadol more diffi-
cult at this level. Also, tramadol and tapentadol
advantages and limitations are highly dependent on
the context of use. Indeed, if patients with a poly-
morphic CYP2D6 isoenzyme are concerned, the use
of tapentadol will be a more appropriate option.
Therefore, the choice of opioid to be prescribed
should be based on the individual patient character-
istics and aims of the treatment.
8. Abuse liability
Tramadol has a dual mechanism of action, present-
ing a low abuse potential, although it is not com-
pletely devoid of risk. Indeed, given that tramadol
inhibits serotonin reuptake and promotes dopamine
release, and as the levels of these neurotransmitters
are involved in the regulation of mood, its potential
for addiction should be considered (Barber, 2011).
Shadnia et al. (Shadnia et al., 2008) analysed 114
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cases of intentional tramadol intoxications at the
Loghman-Hakim Hospital Poison Center, in Iran.
Most cases concerned young adults, upon oral
administrations, and with cardiopulmonary arrest
being the cause of death. However, and according to
other studies, tramadol mortality was low (Musshoff
and Madea, 2001; Shadnia et al., 2008). Tramadol
co-administration with other drugs was detected in
only 28.95% of all cases. The rationale for this study
was the fact that, in Iran, tramadol overdose has
been one the most frequent causes of drug intoxica-
tion, and the most common reason for admission
into the Loghman-Hakim Hospital Poison Center
(Shadnia et al., 2008). Iranian adolescents were
found to use tramadol in combination with ethanol,
cannabis and ecstasy (Shadnia et al., 2008; Nazarza-
deh et al., 2014). The use of one drug is associated
with the propensity to use other drugs, but there are
other possibilities to explain the higher use of tra-
madol in Iran, such as the family background and
social perceptions about tramadol safety, as it is a
prescription medication (Nazarzadeh et al., 2014).
The higher rates of tramadol intoxication in Iran
may be related to the higher frequency of UMs in
Saudi Arabians (20%), as M1 levels increase in this
phenotype. Genotyping could help in the interpreta-
tion of intoxication cases, as well as in the reduction
of their frequency in these countries (LLerena et al.,
2014; Lassen et al., 2015). In turn, tramadol use is
also common among the Egyptian adolescent popu-
lation, from which one-third of all users had drug-
related problems (Bassiony et al., 2015). Although
tramadol users report a sense of happiness deriving
from its consumption, it is also known to cause cog-
nitive alterations (Bassiony et al., 2015). Randall and
Crane, in a review, analysed several cases of tra-
madol deaths in Northern Ireland from 1996 to 2012
(Randall and Crane, 2014). A total of 127 cases were
reported, from which 49% concerned the combina-
tion of tramadol with other drugs/medicines and
23% the intake of tramadol alone (Randall and
Crane, 2014). These authors also reported a 10%
increase in tramadol-related deaths, representing
40% of all drug-related deaths in 2011, although
few changes in prescribing have been documented
(Randall and Crane, 2014). In turn, Tjaderborn and
co-authors studied fatal unintentional tramadol
intoxications in Sweden, in the period comprised
between 1995 and 2005. In all cases, other drugs
were detected in addition to tramadol, although in
seven cases tramadol was the only substance
detected at toxic concentrations, while eight cases
(47% of the total) were associated with a history of
tramadol abuse (Tjaderborn et al., 2007). These
authors alert to risks of tramadol prescription, partic-
ularly for subjects with abuse history (Tjaderborn
et al., 2007).
In this context, according to the Intercontinental
Marketing Services (IMS) Kilochem data, tramadol
worldwide consumption increased 42% between
2006 and 2012 (Abdel-Hamid et al., 2016). In line
with this, tramadol was included in the annual
report for 2013 by the International Narcotics Con-
trol Board (INCB), and five countries reported a sig-
nificant risk of tramadol abuse (Abdel-Hamid et al.,
2016). In several countries, tramadol use and abuse
are serious problems, and numerous countries, such
as Iran, Venezuela, Sweden, Ukraine, Egypt, Aus-
tralia, Brazil, Japan, China, the United Kingdom and
the United States, have put tramadol under national
control (Lanier et al., 2010; Ojha and Bhatia, 2010;
Babalonis et al., 2013). In developed countries, the
increase in prescription is a problem. For instance, in
the United Kingdom, tramadol prescription had a
50% increase, as well as 77% increase in tramadol-
related deaths, between 2009 and 2011 (Verri et al.,
2015).
Considering that MOR activation is responsible for
opioid-related euphoria and mood alterations, and
that tapentadol has lower MOR affinity than classical
opioids (showing, for instance, 18-fold less affinity
than morphine), its risk of abuse liability is poten-
tially lower (Tzschentke et al., 2007; Arjunan et al.,
2015). In fact, several data suggest that tapentadol
abuse is infrequently reported, with the support for
this fact being its dual mechanism of action (Butler
et al., 2015; Pergolizzi et al., 2017). Consistently
with is, prescription volume-adjusted relative risk for
tapentadol ER was the lowest compared to analo-
gous ER formulations, including those of fentanyl,
oxymorphone, morphine, oxycodone and tramadol,
with the exception of hydromorphone. Also, tapen-
tadol IR abuse prevalence was lower than all com-
parators except fentanyl IR (Butler et al., 2015;
Pergolizzi et al., 2017). In turn, to assess tapentadol
tolerance liability, equianalgesic doses of tapentadol
and morphine were administered in rat tail-flick
models, showing that the loss of the antinociceptive
effect was delayed for tapentadol, while rapidly onset
for morphine (Tzschentke et al., 2007; Pergolizzi
et al., 2017). Cepeda et al. (Cepeda et al., 2013a), in
a cohort study using two claims databases, concluded
that patients treated with tapentadol IR have a lower
risk of receiving an abuse diagnosis and developing
abuse/dependence than with oxycodone IR,
although they may happen. A comparative study on
© 2018 European Pain Federation - EFIC! Eur J Pain 22 (2018) 827--844 839
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the likeliness to obtain opioid prescriptions from
multiple prescribers – a phenomenon known as doc-
tor shopping – also concluded that the risk is sub-
stantially lower for tapentadol than for oxycodone
(Cepeda et al., 2013b), as well as the risk of abuse
(Cepeda et al., 2014). Likewise, the Researched
Abuse, Diversion and Addiction-Related Surveillance
(‘RADARS’) system found tapentadol rates of abuse
and diversion to be much lower than those for oxy-
codone or hydrocodone in the first 2 years following
the initial release and marketing of its IR forms in
the United States (Dart et al., 2012). Although there
are reports of nonmedical diversion of tapentadol by
college students, through chewing and swallowing
and inhalation, besides intact swallowing, this was
considered to be the result of a brief experimentation
period following introduction (Dart et al., 2014). In
turn, population-based rates and drug availability of
the diversion of tapentadol ER were slightly lower
than that of tapentadol IR, and significantly lower
than those of other Schedule II opioid medications
(Dart et al., 2016). Another study analysed the mes-
sages posted in online forums for drug abusers,
between January 2011 and September 2012, focus-
ing on the amount of discussion and endorsement
for tapentadol abuse, in comparison with other drugs
(McNaughton et al., 2015). In this study, the num-
ber of posts on tapentadol was significantly lower
than on all other compounds, although slightly
higher than that on tramadol; these authors also
suggest that the dual mechanism of action may be
associated with a lower abuse liability (McNaughton
et al., 2015). Also, a study comparing the effects
after tapentadol, tramadol and hydromorphone
administration concluded that positive subject-rated
effects (reported as ‘good effects’ and ‘like the drug’)
occur earlier and dissipate faster for tapentadol than
for tramadol or hydromorphone, with no negative
side effects associated, which may contribute to
tapentadol potential abuse (Stoops et al., 2013).
Therefore, additional studies are necessary in order
to evaluate tramadol and tapentadol safety and mini-
mize their side effects, as well as to evaluate their
potential for abuse and dependence. Although the
difference in the number of studies concerning tra-
madol and tapentadol abuse potential only reflects
the difference in the length of their marketing peri-
ods, it hinders a truly fair comparison between both
drugs and, as such, the demonstration of an absolute
advantage of tapentadol over tramadol. Taken
together, and despite the low rate of adverse events
and the seemingly lower abuse liability provided by
tapentadol, the results from the studies performed in
this field substantiate the need to carefully balance
the prescription of both drugs.
9. Concluding remarks and future
prospects
Pain physiology is complex and, as a primary sur-
vival mechanism, shows remarkable redundancy and
involves the overlap of numerous sensory pathways.
In this context, the concept of ‘mixed pain’ gains
sense and validates the search for poly-pharmacolo-
gical approaches, as well as for multifunctional and
multitarget drugs. Mixed MOR agonists and monoa-
mine reuptake inhibitors, such as tramadol and
tapentadol, engage different CNS pathways, enhanc-
ing analgesia and reducing undesirable adverse
effects.
Despite their structural and pharmacodynamic
similarities, it should be emphasized that tramadol
and tapentadol have different MOR affinities
(Table 2), which justifies their inclusion in different
classes. In fact, tramadol belongs to class II, accord-
ing to the WHO Guideline Cancer Pain Relief, being
meant for mild-to-moderate pain treatment, while
tapentadol belongs to class III, regarding the treat-
ment of moderate to severe pain. Besides, while tra-
madol is a Schedule 4 drug (with a lower abuse
potential and physical and psychological dependence
than Schedule 3 drugs), tapentadol belongs to
Schedule 2, being accepted for medical use in several
countries, but with severe restrictions. While tra-
madol is available as an analgesic since the late
1970s, tapentadol has been approved in the late
2000s. In spite of providing an overall low rate of
adverse events, tramadol was shown to have a con-
siderable dependence and abuse potential. Given the
contribution of the MOR component to dependence
and abuse, and considering the more pronounced
NA reuptake inhibition component of tapentadol, it
shows comparable analgesic efficacy to other strong
opioids, but considerably less side effects and abuse
potential. Its minimal serotonergic effect, along with
evidences of enhanced gastrointestinal tolerability
and no negative effects on neurogenesis, makes it a
promising alternative for the treatment of chronic
and neuropathic pain. Moreover, unlike tramadol
and oxycodone, tapentadol does not depend on the
CYP450 system to produce more active metabolites,
thereby circumventing interindividual differences in
metabolizer phenotypes, providing linear and pre-
dictable pharmacokinetics and minimizing the need
for dose adjustments. However, recent in vitro and
in vivo studies using tramadol and tapentadol
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equimolar concentrations have reinforced available
data on the toxicological potential of tramadol and
showed that the toxicological potential of tapentadol
is at least comparable. Although tapentadol seems to
entail lower abuse, addiction and diversion liability,
it has been associated with more severe outcomes,
when compared to tramadol, in the clinical setting.
Therefore, additional in vitro and in vivo, randomized
double-blind controlled studies are required to estab-
lish tapentadol efficacy, safety and long-term abuse
liability. Likewise, tapentadol safety on the paediatric
population and in patients with renal and hepatic
commitment needs to be further determined. In
order to help patient rotation to or from tapentadol,
the establishment of more dose-conversion ratios
would also be useful.
Accordingly, further research on tapentadol is
needed to gather long-term efficacy and safety data
to reach an equitable comparison between this drug
and tramadol and other opioids. We believe that
such information will accumulate in the next years,
along with the increasing clinical experience that is
expected for tapentadol within the same period,
given its potential advantages over comparator
drugs.
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The overall aim of the present thesis was to comparatively study the toxic effects 
associated with tramadol and tapentadol exposure, using in vitro and in vivo models. 
While tramadol is one of the most prescribed opioids worldwide, tapentadol is a more 
recent drug, associated with a higher analgesic effect than tramadol, but has raised 
many doubts about its toxicity and dependence among the scientific community. In fact, 
very few studies on its toxic effects and safety have been performed, which difficult the 
comparative analysis of safety between both drugs. 
With this thesis, an increase in the knowledge in the opioid toxicology field is 
aimed, by providing new data on the molecular and mechanistic aspects of tramadol 
and tapentadol toxicity. It is also expected to provide an insight into the damage in 
target organs: brain, lung and heart, as well as about alterations on biochemical 
parameters. A comparative analysis of the results obtained upon exposure to both drugs 
might contribute to a more conscious prescription and consumption, besides helping in 
the identification and explanation of intoxication and fatal intoxication cases. 
The hypothesis derived from these general objectives supported the specific goals 
of the original research corresponding to the two chapters of this thesis, as described 
below: 
 
 
CHAPTER I  
 
In order to assess the potential neurotoxicity of tramadol and tapentadol, an in vitro 
model of nervous system cells was used. Nervous cells were acutely exposed to both 
opioids. The studies were addressed considering four aspects: 
1. A comparative evaluation of the potential neurotoxicity of both opioids; 
2. The evaluation of cell viability and the mechanisms of death promoted by 
each drug; 
3. The role of oxidative stress and mitochondrial integrity in cell toxicity;  
4. The assessment of the metabolic alterations.  
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CHAPTER II 
 
In order to complement the in vitro approach, in vivo studies, using male Wistar 
rats, were performed to analyse the effects induced by an acute exposure to effective 
(analgesic) doses. The analyses were performed in blood samples and in brain, lung 
and heart specimens. The methodologies used aimed at the evaluation of: 
1. The analysis of the potential biochemical changes in serum and brain 
samples; 
2. The assessment of the oxidative stress damage in brain, lung and heart tissues; 
3. The evaluation of the potential histopathological alterations in brain, lung and 
heart tissues. 
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A B S T R A C T
Opioid therapy and abuse are increasing, justifying the need to study their toxicity and underlying
mechanisms. Given opioid pharmacodynamics at the central nervous system, the analysis of toxic effects
in neuronal models gains particular relevance. The aim of this study was to compare the toxicological
effects of acute exposure to tramadol and tapentadol in the undifferentiated human SH-SY5Y
neuroblastoma cell line. Upon exposure to tramadol and tapentadol concentrations up to 600 mM, cell
toxicity was assessed through evaluation of oxidative stress, mitochondrial and metabolic alterations, as
well as cell viability and death mechanisms through necrosis or apoptosis, and related signalling.
Tapentadol was observed to trigger much more prominent toxic effects than tramadol, ultimately leading
to energy deficit and cell death. Cell death was shown to predominantly occur through necrosis, with no
alterations in membrane potential or in cytochrome c release. Both drugs were shown to stimulate
glucose uptake and to cause ATP depletion, due to changes in the expression of energy metabolism
enzymes.
The toxicity mechanisms in such a neuronal model are relevant to understand adverse reactions to
these opioids and to contribute to dose adjustment in order to avoid neurological damage.
ã 2016 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Tramadol and tapentadol are centrally acting, synthetic opioid
analgesics widely used in the treatment of moderate to severe pain
(Hartrick and Rozek 2011; Pinho et al., 2013; Zhou 2009 ). Tramadol
is the most commonly prescribed opioid and tapentadol use is
increasing (Meske et al., 2013; Raffa et al., 2012). Although
tapentadol does not require metabolic activation, tramadol owes
most of its analgesic effect to its main active metabolite, O-
desmethyltramadol (M1), although the parent compound exhibits
some pharmacological activity (Grond and Sablotzki 2004;
Hartrick and Rozek 2011). Their clinical interest is mostly due to
their low incidence of side effects, when compared with classical
opioids such as heroin and morphine (Hartrick and Rozek 2011).
Nevertheless, respiratory depression and fatal intoxications have
been reported for these compounds (Costa et al., 2013; Dinis-
Oliveira et al., 2012a; Dinis-Oliveira et al., 2012b; Larson et al.,
2012; Pinho et al., 2013; Ryan and Isbister 2015), and brain lesions
were found in one subject with a history of tramadol abuse in a
study that analysed 28 subjects (Boostani and Derakhshan 2012).
Although serotonin syndrome is often associated with tramadol, a
recent study by Ryan and Isbister did not detect serotonin toxicity
in overdose cases with tramadol (Ryan and Isbister 2015; Sansone
and Sansone 2009 ). However, when excessive use or co-
administration of other drugs (particularly antidepressants) take
place, the risk of serotonin toxicity is considerable (Sansone and
Sansone 2009 ).
Chronic use of tramadol has been associated with red neuron
degeneration in rat brains, which has been raised as a possible
explanation for cerebral dysfunction (Atici et al., 2004). This fact
* Corresponding authors at: IINFACTS—Institute of Research and Advanced
Training in Health Sciences and Technologies, Department of Sciences, University
Institute of Health Sciences (IUCS), CESPU, CRL, Gandra, Portugal.
E-mail addresses: julianaffaria@gmail.com (J. Faria), ricardinis@sapo.pt
(R.J. Dinis-Oliveira).
http://dx.doi.org/10.1016/j.tox.2016.06.010
0300-483X/ã 2016 Elsevier Ireland Ltd. All rights reserved.
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emphasizes the need for the analysis of the effects in humans,
particularly concerning neurotoxicity and central nervous system
dysfunction upon tramadol and tapentadol administration,
similarly to what happens with other drugs of abuse of this
class. Neurotoxicity has been claimed to be due to oxidative
stress, mitochondrial changes, apoptosis and neurogenesis
inhibition, as suggested by proteomic assays with zebrafish brain
(Zhuo et al., 2012). Since tramadol presents positive charge at
physiological pH, it may accumulate within negatively charged
cell compartments such as mitochondria, eventually causing
mitochondrial dysfunction, similarly to what happens with
cocaine derivatives (Cunha-Oliveira et al., 2008). As the neuro-
toxic mechanisms of tramadol and tapentadol are not fully
understood, the present work aims to study the in vitro toxic
effects of these opioids in a human neuronal model, the SH-SY5Y
cell line, namely by assessing oxidative stress, mitochondrial and
metabolic alterations, as well as cell viability through necrosis or
apoptosis, and related signalling.
2. Materials and methods
2.1. Cell culture
SH-SY5Y cells (ATCC, Manassas, VA, USA) were maintained in
25 cm2 flasks, being regularly observed through microscopy.
Cells were routinely subcultured to new flasks, by trypsinization
[Trypsin EDTA 1 ! (ScienCell)], when they were approximately 70–
90% confluent. SH-SY5Y cells were cultured in complete growth
medium consisting of DMEM with 1% (v/v) GlutaMAXTM and
4.5 g/L glucose (Lonza), supplemented with 10% (v/v) Fetal Bovine
Serum (FBS, Gibco Invitrogen), 1% NEAA (Non-Essential Amino
Acids, Gibco Invitrogen), 100 U/mL of penicillin and 100 mg/mL of
streptomycin (Sigma-Aldrich). Cells were maintained in a humidi-
fied incubator (Heraeus Hera Cell), at 37 "C and 5% CO2 atmosphere.
Before each assay, after seeding, cells were incubated for 24 h in the
humidified incubator, allowing them to stabilize and adhere,
before exposure to tramadol/tapentadol.
2.2. Drug preparation
Stock solutions of tramadol hydrochloride (Sigma-Aldrich) and
tapentadol hydrochloride (Deltaclon) were freshly prepared in
sterile water, with the appropriate dilutions (5 concentration
levels) being made in complete medium. Cells were exposed to
different drug concentrations (up to 600 mM) for 48 h at 37 "C and
5% CO2.
2.3. Cytotoxicity assays
Cytotoxicity was assessed through MTT and SRB (sulforhod-
amine B) assays. Cell suspensions with a final density of 1.5 !105
cells/ml were prepared in growth medium containing 5% FBS and
lacking antibiotic/antimycotic mixture and cells were seeded in 96
well-plates (1.5 !104 cells/well) and exposed to tramadol and
tapentadol. Non-exposed cells were used as controls, and wells
without cells and with compound were used as blanks for each
concentration.
2.3.1. MTT assay
MTT assay measures dehydrogenase activity, an indicator of
metabolically active mitochondria, and thus of cell viability. After
48 h of exposure to tramadol and tapentadol at 37 "C and 5% CO2,
cells were incubated for 4 additional hours with 200 ml of DMEM
containing 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium (MTT; Sigma-Aldrich). After incubation, the cell
culture medium was removed, and formazan crystals were then
solubilized by adding 100 ml of solubilization solution [(89% (v/v)
isopropanol, 10% (v/v) Triton X-100, 1% (v/v) of HCl 0.37% (w/v)].
Upon homogenization, absorbance values were read at 550 nm in
a plate reader (Biotek Synergy 2) and retrieved using Gene5
software (Biotek). Dose-response curves were plotted using
GraphPad Prism1 version 5.0c. Results were presented as the
percentage of cell viability versus concentration. All drugs were
tested in 5 independent experiments, with each concentration
tested in 6 replicates within each experiment.
2.3.2. SRB assay
The SRB assay is an indicator of cell density, based on the
measurement of cellular protein content. Before cell exposure to
tramadol/tapentadol, an identical, additional plate (T0 plate) was
fixed with 50 ml 50% (w/v) pre-cold trichloroacetic acid and by
incubating 1 h at 4 "C, in order to determine the initial amount of
cells used in the assay. After 48 h of tramadol/tapentadol exposure
at 37 "C and 5% CO2, cells were fixed as described for the T0 plate.
After fixation, the plates were washed 5 times with deionized
water and air-dried at room temperature. Then, cell proteins were
stained with 50 ml 0.4% (w/v) SRB (Sigma-Aldrich) in 1% (v/v) acetic
acid, followed by a 30 min-incubation. SRB was then removed
through 5 washings with 1% (v/v) acetic acid. The plates were again
allowed to dry at room temperature. In order to solubilize protein/
SRB complexes, 100 ml of 10 mM Tris buffer were added to each
well. Absorbance of each well was measured at 515 nm in a plate
reader (Biotek Synergy 2). Dose-response curves were plotted
using GraphPad Prism1 version 5.0c. Results were presented as the
percentage of cell viability versus concentration. All drugs were
tested in 5 independent experiments, with each concentration
tested in 6 replicates within each experiment. The T0 plate was
used to determine the amount of cells present by the time that the
compound was added, and the mean absorbance value was
subtracted to the absorbance value of the wells containing the
compound, upon exposure.
2.4. Trypan blue assay
After tramadol/tapentadol incubation, cells were trypsinized
and cell viability was determined through the trypan blue
exclusion method. Non-exposed cells were used as controls.
2.5. TBARS and carbonyl groups
For the preparation of cell suspensions, cells were cultured in
complete growth medium in T25 flasks until 70% of confluence.
After exposure to tramadol/tapentadol, the medium was removed
and cells were washed with PBS and collected through
trypsinization. Non-exposed cells were used as controls. Culture
medium was used to prepare blank samples. Cells were
centrifuged (860g, 4 min) and the supernatant was removed. Cell
pellets were lysed with lysis buffer [(50 mM Tris-HCl, pH 7.5;
30 mM NaCl; 0.5% (v/v) Triton X-100; 1 mM EDTA; protease
inhibitor cocktail 1!)], incubated on ice for 20 min and then
centrifuged at 19,330g for 15 min, 4 "C. The obtained supernatants
were acidified with 10% (v/v) perchloric acid and used for TBARS
(thiobarbituric acid-reactive substances) quantification, whereas
the pellets were used for carbonyl group quantification. Lipid
peroxidation (LPO) was evaluated using the well-known TBARS
methodology (Buege and Aust 1978), with the results being
expressed as nanomoles of malondialdehyde (MDA) equivalents
per milligram of protein used. Protein carbonyl groups (ketones
and aldehydes) were determined according to Levine et al. (Levine
et al., 1994) and the results were expressed as nanomoles of 2,4-
dinitrophenylhydrazine (DNPH) incorporated per milligram of
protein.
2 J. Faria et al. / Toxicology 359  (2016) 1–10
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2.6. Detection of apoptosis by annexin V-FITC apoptosis and TUNEL
assays
Cell death by apoptosis was analysed using the TUNEL kit assay
(DeadEndTM Colorimetric TUNEL System, Promega) and through
staining with annexin V-FITC and propidium iodide, PI (annexin V-
FITC Detection Kit, Biotool). In these assays, cells were plated in 6-
well plates (1.5 !104 cells/well) with coverslips and exposed to
tramadol and tapentadol for 48 h. The results were analysed under
fluorescence microscopy in a Zeiss Spinning Disc AxioObserver Z.1
SD microscope, coupled to an AxioCam MR3 camera. Representa-
tive focus plans were chosen for image acquisition, which was
performed using the AxioVision 4.8.2 software.
In the annexin V-FITC assay, after 48 h of tramadol/tapentadol
exposure at 37 "C and 5% CO2, cells were washed with cold PBS.
Then, 5 ml annexin V-FITC, 5 ml PI and 90 ml binding buffer were
added, followed by incubation at room temperature, in the dark,
for 15 min. Cells were washed in PBS for 5 min, and coverslips were
then mounted in 40,6-diamidino-2-phenylindole (DAPI). Positive
control cells were treated with H2O2. Non-treated cells were used
as negative controls.
In the TUNEL assay, after 48 h of tramadol/tapentadol exposure
at 37 "C and 5% CO2, cells were fixed through immersion in a 4% (v/
v) paraformaldehyde solution in PBS, for 25 min, at 4 "C. Then, they
were washed twice with PBS and permeabilized with a 0.2% (v/v)
Triton X-100 solution in PBS, and washed again with PBS. Upon
washing, cells were incubated with 100 ml of Equilibration Buffer
for 10 min, and then incubated with rTdT Incubation Buffer
(composition per standard 50 ml reaction: 45 ml Equilibration
Buffer, 5 ml Nucleotide Mix, 1 ml rTdT Enzyme) for 1 h at 37 "C. The
reaction was stopped by washing cells with 2 ! SSC for 15 min, at
room temperature. Coverslips were then washed with PBS, and
mounted in DAPI. Cells treated with DNaseI (Fermentas) were the
positive control. Non-exposed cells were used as negative controls.
2.7. Caspase activity assay
For the preparation of cell suspensions, cells were cultured in
complete growth medium in 6 well-plates (2 ! 105 cells/well).
Incubation time and assay conditions were previously optimized.
After incubation with tramadol/tapentadol for 48 h, the medium
was removed and the cells were washed with PBS, and 150 ml of
Glo Lysis Buffer (Promega) were added to each well. Cells were
incubated for 5 min at room temperature. The lysates were
collected and frozen at # 20 "C. The results were normalized
against protein content and the final results expressed as the
percentage of the control (cells that had not been exposed to
tramadol and tapentadol) from 5 independent experiments, tested
in 2 replicates within each experiment, totalling 10 analyses for
each concentration.
2.7.1. Caspase-3
Caspase-3 activity was determined as described by Barbosa
et al., 2014 (Barbosa et al., 2014). 50 ml of each lysate was mixed
with 200 ml assay buffer (100 nM HEPES (pH 7.5), 20% (v/v)
glycerol, 5 mM DTT, 0.5 mM EDTA) and 5 ml of the caspase-3
peptide substrate Ac-DEVD-pNA (Sigma-Aldrich) (final concentra-
tion 80 mM), in 96 well-plates, followed by incubation at 37 "C for
24 h. Caspase-3 activity was determined at 405 nm, by quantifying
the reaction product, using a microplate reader (Biotek Synergy 2).
2.7.2. Caspase-9
Lysates (10 ml) were mixed with 200 ml of assay buffer (100 nM
HEPES (pH 7.5), 20% (v/v) glycerol, 5 mM DTT, 0.5 mM EDTA) in 96
well-plates, followed by incubation at 30 "C for 30 min. After
incubation, the reaction was started by adding 10 ml of caspase-9
fluorogenic substrate N-acetyl-Leu-Glu-His-Asp 7-amido-4-tri-
fluoromethylcoumarin (Sigma-Aldrich) (final concentration
180 mM). Fluorescence was determined using a microplate reader
(Biotek Synergy 2) to 400 nm excitation and 500 nm emission, in a
kinetic reaction for 5 min.
2.8. Measurement of intracellular ATP levels
Regarding the preparation of cell suspensions, cells were
cultured in complete growth medium in 6 well-plates (2 ! 105
cells/well). Upon incubation with tramadol/tapentadol, the
medium was removed and the cells were washed with PBS
and recovered through trypsinization. Cells were then centri-
fuged (860g, 4 min) and the supernatant removed. The pellets
were lysed with lysis buffer [50 mM Tris-HCl, pH 7.5; 30 mM NaCl;
0.5% (v/v) Triton X-100; 1 mM EDTA; protease inhibitor cocktail
1!], incubated for 20 min on ice, and then centrifuged at 19,330g
for 15 min, 4 "C. The supernatants obtained were frozen at # 20 "C
and used to quantify ATP. Cellular ATP levels were quantified with
the ATP determination kit (Molecular Probes #  Invitrogen)
according to the manufacturer's instructions, and solutions have
been protected from light. Bioluminescence was determined using
a microplate reader (Biotek Synergy 2) with an appropriate black
plate. Six calibration standards were prepared in order to plot a
standard curve, and the background luminescence was sub-
tracted. The results were normalized against protein content and
the final results were expressed as the percentage of control (cells
that had not been exposed to tramadol and tapentadol) from 5
independent experiments, with each concentration tested in 2
replicates within each experiment, totalling 10 analyses for each
condition.
2.9. Assessment of mitochondrial membrane potential (DCm)
Assessment of mitochondrial integrity was performed by
measuring tetramethylrhodamine ethyl ester perchlorate (TMRE)
inclusion as previously described (da Silva et al., 2014). In order to
prepare cell suspensions, cells were seeded in complete growth
medium in 96 well-plates (1.5 !104 cells/well). Cells were exposed
to different drug concentrations (up to 600 mM), and the
compounds were allowed to act for 48 h at 37 "C and 5% CO2, in
order to reproduce MTT and SRB assay conditions. Cells lacking
compound exposure were used as controls. Upon exposure, culture
medium was removed and replaced by fresh medium containing
2 mM TMRE (Sigma-Aldrich), followed by incubation in the dark,
for 30 min at 37 "C. Then, the medium was removed and 0.2% BSA in
HBSS was added to each well. Fluorescence was determined using a
microplate reader (Biotek Synergy 2), at 544 nm excitation and
590 nm emission. The results were expressed as the percentage of
control (cells lacking exposure to tramadol and tapentadol) from 5
independent experiments, with each concentration tested in 6
replicates within each experiment.
2.10. Protein quantification
Proteins were quantified with the Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific), according to the manufacturer’s
instructions, using bovine serum albumin as standard.
2.11. Measurement of cytochrome c release
For the preparation of cell suspensions, cells were cultured in
complete growth medium in T25 flasks. After exposure to
tramadol/tapentadol for 48 h, the media were recovered and cells
were washed with PBS, collected through trypsinization and
combined with the recovery medium. This suspension was
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centrifuged (2000g, 5 min) and the supernatant was removed. The
pellet was lysed with lysis buffer (250 mM sucrose, 50 mM Tris-
HCl, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, pH 7.4),
followed by incubation for 15 min on ice, and then centrifuged
at 15,000g for 15 min, 4 !C. The supernatant (cytosolic fraction)
and the pellet (mitochondrial fraction) were frozen at " 20 !C.
Cytochrome c levels in the cytosolic and mitochondrial fractions
(20 mg protein) were analyzed by Western blot. The extracts were
separated by SDS–PAGE, on a 12% acrylamide separating gel. Then,
proteins were transferred (60 mA for 60 min) to a nitrocellulose
membrane. Proteins were stained with Ponceau S in order to
confirm a homogeneous loading. Membranes were blocked with
10% non-fat dried milk in TBST (10 mM Tris/HCl, pH 7.5, 150 mM
NaCl, and 0.2% Tween 20) at 4 !C for 1 h and probed with anti-
cytochrome c primary antibody (sc-13560, Santa Cruz Biotechnol-
ogy) (diluted 1:250 in TBST with 5% non-fat dried milk) overnight.
Then, membranes were incubated for 1 h with peroxidase-
conjugated secondary antibodies (diluted 1:2000 in TBST with
5% non-fat dried milk), and washed (3 times for 10 min). Bands
were visualized by treating the immunoblots with ECL (enhanced
chemiluminescence) and analyzed with the QuantityOne Software
(Bio-Rad).
2.12. Biochemical parameters: glucose and lactate levels
Cell lysates were prepared as described in the “Measurement of
intracellular ATP levels” section. Glucose and lactate intracellular
levels were quantified by Prestige 24i automated analyzer (Tokyo
Boeki) according to the manufacturer’s instructions, using 2
appropriate calibrators, which were diluted to plot a standard
curve with 5 points. A quality control was also used (Costa et al.,
2015).
Results were normalized against total protein content and
against the respective control (non-treated cells).
2.13. RNA extraction and cDNA synthesis
For the preparation of cell suspensions, cells were seeded in
complete growth medium in 6 well-plates (2 # 105 cells/well).
After cell exposure to different concentrations of tramadol and
tapentadol during 48 h, total RNA was extracted using PureZol
(Bio-Rad), with 500 ml PureZol/well, according to the manufactur-
er's instructions. cDNA was synthesized from 1 mg total RNA, using
the High capacity cDNA Reverse Transcriptase kit (Applied
Biosystems), according to the manufacturer's directions.
2.14. Real-time PCR
The primers used for the analysis of gene expression through
qReal-Time PCR are described in Table 1. Each reaction mixture
had a total volume of 25 ml, comprising 12.5 ml 2 #  SYBR Green
mix (BioRad); 2 ml cDNA diluted 1:10; 0.25 ml forward primer;
0.25 ml reverse primer and 10 ml RNase-free H2O. The PCR
amplification program comprised an initial denaturation step
at 95 !C for 3 min, followed by 55 denaturation cycles at 95 !C for
10 s, primer annealing at 52 !C for 20 s, extension at 72 !C for 20 s
and plate read. Upon the cycling steps, the melt curve was
performed from 55 !C to 95 !C, with 0.5 !C increments for 5 s,
followed by a plate read. Lactate dehydrogenase (LDH), Fe-S
protein 1 of NADH dehydrogenase (NDUFS1), creatine kinase B
(CKB), pyruvate dehydrogenase kinase 3 (PDK3) and aldolase C
(ALDOC) genes were analyzed, and 18 S ribosomal RNA was used
as housekeeping gene. Results were normalized against those of
non-exposed cells.
2.15. Statistical analysis
Results were expressed as means $  SD. All analyses comprised
at least 6 replicates performed in 3 independent assays. The
graphics were plotted using GraphPad Prism1 version 5.0c.
Statistical data analysis was performed as an Analysis of Variance
(ANOVA). Probability values of p %  0.05 were considered to be
significant.
3. Results
3.1. Toxicity of tramadol and tapentadol in SH-SY5Y cells
Human cell line SH-SY5Y was exposed to tramadol and
tapentadol. In order to understand what happens in extreme
situations, such as intoxication and fatal cases, high concentrations
of both opioids were used (Costa et al., 2013; Kemp et al., 2013;
Larson et al., 2012; Shadnia et al., 2008). Indeed, in therapeutic
doses (single oral dose of 100 mg) maximum serum concentrations
(Cmax) were approximately 1 mM for tramadol (Grond and
Sablotzki 2004; Raffa et al., 2012) and 0.5 mM for tapentadol
(Raffa et al., 2012). Other authors have used high opioid
concentrations in similar studies, such as that of Perez-Alvarez
et al., who exposed SH-SY5Y cells to methadone concentrations up
to 1000-fold its Cmax (Bruce et al., 2013; Perez-Alvarez et al., 2010).
Regarding postmortem cases, tramadol and tapentadol concen-
trations are highly variable. Indeed, tramadol concentrations of
7.7 mg/L and 48.34 mg/L were reported, while 3.2 mg/L and
0.77 mg/L were found for tapentadol in postmortem blood samples
(Costa et al., 2013; De Backer et al., 2010; Kemp et al., 2013; Larson
et al., 2012). Thus, given the variability in maximum postmortem
blood concentrations, our aim was to ascertain the damage extent
in a broader concentration range. Upon exposure, toxic effects
were evaluated through MTT and SRB assays (Fig. 1). The obtained
results suggest that, within the concentrations and exposure
period tested, tapentadol shows higher toxicity than tramadol. In
fact, tapentadol has a more pronounced effect than tramadol on
the decrease of metabolic activity (Fig. 1A), and cell biomass
(Fig. 1B). These effects are also reflected in cell viability. This was
observed both qualitatively, through morphologic alterations
(from the increase in the amount of round, suspension cells in
the culture), and quantitatively, through the trypan blue method,
reflected on the significant increase in the amount of dead cells
(Fig. 2).
Table 1
Primers used for Real-Time PCR amplification of each gene.
Gene Forward Primer Reverse Primer Reference
LDH-A (lactate dehydrogenase) AGCCCGATTCCGTTACCT CACCAGCAACATTCATTCCA Yu et al. (2014)
ALDOC (aldolase C) GCGCTGTGTGCTGAAAATCAG CCACAATAGGCACAATGCCATT Walczak-Drzewiecka et al. (2008)
NDUFS1 (Fe-S protein 1 of NADH dehydrogenase) TCGGATGACTAGTGGTGTTA TTATAGCCAAGGTCCAAAGC Yang et al. (2014)
PDK3 (pyruvate dehydrogenase kinase 3) TTAATAAGTCCGCATGGCGC TGAAGCATCCCTGGGTTCAC Lu et al. (2008)
CKB (creatine kinase b) CCTTCTCCAACAGCCACAAC CAGCTCCGCGTACAGCTC Pfefferle et al. (2011)
18 S ribosomal RNA CAACATCGATGGGCGGCGGA CCCGCCCTCTTGGTGAGGTC
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3.2. Oxidative stress does not contribute to the toxic effects
In order to evaluate the mechanisms of toxicity that are elicited
by tramadol and tapentadol, TBARS and protein carbonyl group
levels were determined. As shown in Fig. S1A and B, no significant
differences in oxidative stress parameters were found, compara-
tively to untreated cells, suggesting that the toxicity caused by
tramadol and tapentadol is not predominantly caused by oxidative
damage.
3.3. Necrosis is the main mechanism of cell death elicited by tramadol
and tapentadol
In order to assess the mechanism of tramadol and tapentadol
toxicity and cell death, different assays were performed. TUNEL
assays (Fig. 3A) showed that tapentadol induces some signs of
apoptosis. However, annexin V-FITC labelling (Fig. 3B) showed that
necrosis is the main mechanism responsible for cell death
following exposure to both drugs. Cytochrome c release assays
(Fig. S2) showed no alterations in the presence of both drugs, when
compared to non-exposed cells. Caspase activity quantification
(Fig. 4) corroborates these results, since only a slight increase was
detected upon tapentadol exposure. In order to evaluate if
tramadol and tapentadol lead to mitochondrial damage, the
mitochondrial membrane potential was assessed (Fig. S3). No
significant differences were found in the presence of tramadol or
tapentadol, when compared to the control. Thus, the mitochon-
drial integrity is not affected by tramadol/tapentadol. These results
are in accordance with the fact that no significant increase in
cytochrome c release was detected and with the results pointing to
necrosis as being the main mechanism of cell death triggered by
tramadol/tapentadol (Fig. S2).
3.4. Tramadol and tapentadol induce changes in energetic metabolism
When SH-SY5Y cells were exposed to tramadol and tapentadol,
an increase in intracellular lactate and glucose (Fig. 5), as well as a
decrease in ATP levels (Fig. 6), were observed, comparatively to
untreated cells, with this effect being dependent on drug dose.
When toxic tramadol concentrations (600 mM) and tapentadol
(200 mM) were used, significant increases in intracellular glucose
and lactate were detected (Fig. 5). Glucose levels (Fig. 5A)
increased 1.77 ! 0.16 fold after exposure to tramadol, and
1.78  ! 0.09 after exposure to tapentadol. Lactate levels (Fig. 5 B)
increased 1.51 !0.21 fold and 1.47 ! 0.30 fold after exposure to
tramadol and tapentadol, respectively. At low tramadol/tapentadol
concentrations (100 mM), there were no significant changes in
glucose and lactate levels. According to these results, both
tramadol and tapentadol were shown to promote a decrease in
ATP levels, suggesting alterations in energetic metabolism. In ATP
quantification, the results show that there is a general trend
towards the decrease in total ATP content, particularly when cells
are exposed to high tramadol (600 mM) and tapentadol (200 mM)
concentrations " a decrease in the order of 24.6% ! 9.3 after
tramadol exposure, and 42.0% ! 16.3 after tapentadol exposure.
However, comparing the results obtained for the 200 mM
concentration, tapentadol induced a higher reduction (to
42.0% ! 16.3) in ATP levels than tramadol (reduction to
73.3% ! 17.0). At low concentrations (100 mM), only tapentadol
caused a significant decrease in ATP (reduction to 60.9% ! 16.4).
Once tramadol and tapentadol were shown to increase extracellu-
lar glucose and lactate levels and to decrease ATP levels, some
Fig. 2. Cell viability upon exposure to tramadol (Tram) and tapentadol (Tap), for
48  h. Cell viability was determined through the trypan blue assay, as the ratio
between the number of living cells and the total amount of cells. ***p < 0.001,
**p < 0.01, *p < 0.05.
Fig. 1. MTT (A) and SRB (B) assays, upon exposure of SH-SY5Y cells to tramadol or
tapentadol for 48  h. Results are expressed by means ! SD, from at least 5
independent assays, with each concentration tested in 6 replicates within each
experiment.
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assays were performed in order to clarify whether there were
changes in the expression of energetic metabolism enzymes
(Fig. 7 ). The results showed that cells exposed to both drugs
presented a decrease in the expression of lactate dehydrogenase
(LDH), Fe-S protein 1 of NADH dehydrogenase (NDUFS1) and
creatine kinase B (CKB), and an increase in the expression of
pyruvate dehydrogenase kinase 3 (PDK3) and aldolase C (ALDOC).
After exposure of the cells to 600 mM tramadol or to 200 mM
tapentadol, LDH, NDUFS1 and CKB levels decreased upon
tramadol/tapentadol exposure. PDK3 levels increased after
Fig. 3. TUNEL (panel A) and annexin V-FITC (panel B) labelling of SH-SY5Y cells upon exposure to 600 mM tramadol (Tram) and 200 mM tapentadol (Tap). DNase-treated cells
and 50 mM H2O2were used as positive controls for apoptosis and necrosis, (panels A and B, respectively). DNA was stained with DAPI. DNA nick ends (panel A) and annexin V-
FITC (panel B) were stained green, and necrotic cells were stained with and propidium iodide (panel B). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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tramadol/tapentadol exposure. ALDOC expression levels were only
significantly altered after tapentadol exposure.
4. Discussion
Tramadol and tapentadol are widely prescribed synthetic
opioid analgesics. Therefore, it is important to further evaluate
its safety, in order to improve therapeutic strategies and prevent
adverse effects, namely when these drugs are used in high doses.
Few studies have been focused on the toxicological assessment of
these opioids in neuronal cells, particularly concerning tapentadol,
since it is a more recent drug that is often administered as a safer
alternative to tramadol (Iyer et al., 2015). Indeed, this is, to our
knowledge, the first study dealing with the comparative toxic
potential of tramadol and tapentadol in an in vitro model of human
neuronal cells. In this work, we used the undifferentiated neuronal
cell line SH-SY5Y, an in vitro model that exhibits many biochemical
and functional characteristics of neurons (Valdiglesias et al., 2013;
Xie et al., 2010), and that is frequently used in neurotoxicity studies
(Di Daniel et al., 2005; Hong et al., 2003; Valdiglesias et al., 2013).
In our study, cells were not differentiated; therefore, they do not
have a dopaminergic phenotype. Tramadol moderately decreased
cell biomass of the SH-SY5Y cell line, whereas tapentadol strongly
decreased cell biomass at concentrations above 200 mM. In fact, as
described by Caputi et al. (Caputi et al., 2014 ), low tapentadol
concentrations (<100 mM) do not appear to cause toxicity in the
SH-SY5Y cell line in MTT assays (Caputi et al., 2014 ). Although low
concentrations did not lead to toxicity, changes in gene expression
have been reported in similar conditions (Caputi et al., 2014 ), for
which it is relevant to test the effects over a broader concentration
Fig. 4. Caspase 3 activity (A) and Caspase 9  activity (B) in SH-SY5Y cells exposed to
600 mM tramadol (Tram) and 200 mM tapentadol (Tap). 200 mM H2O2was used as a
positive control for apoptosis. Quantifications were normalized against the protein
content of the extract. It was also normalized against the value obtained in the
absence of opioid, for each assay, set as 1. Results are expressed as means ! SD,
reflecting at least 10 replicates performed in 5 independent assays. ***p < 0.001,
**p < 0.01, *p < 0.05.
Fig. 5. Glucose (A) and lactate (B) levels in cell lysate after exposure to different
tramadol and tapentadol doses. Glucose and lactate levels were normalized against
the protein content of the extract. They were also normalized against the value
obtained in the absence of opioid, for each cell line, set as 1. Results are expressed as
means ! SD, reflecting at least 6 replicates performed 3 independent assays.
**p < 0.01, *p < 0.05.
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range and evaluate the toxic effects. In the same way, fatal
intoxications by tramadol (Clarkson et al., 2004; Costa et al., 2013;
Shadnia et al., 2008 ) and tapentadol (Kemp et al., 2013; Larson
et al., 2012) have been described, for which it is important to
evaluate their toxicity, and its corresponding mechanisms. We
demonstrate that higher opioid concentrations caused an increase
in toxicity, as assessed by SRB and MTT assays, and corroborated by
the viability assay. In order to evaluate the mechanisms of cell
death induced by the exposure to tramadol/tapentadol, oxidative
stress was estimated through quantification of TBARS and protein
carbonyl group levels, Previously, an increase in oxidative stress,
mitochondrial changes and apoptosis were suggested following
proteomic assays with zebrafish brains after exposure to tramadol
(Zhuo et al., 2012). However, our results suggest that lipid
peroxidation is not an implicated mechanism of toxicity. Combined
cell death analysis through TUNEL and annexin V-FITC assays
indicated that necrosis is the predominant mechanism of cell
death. Consistently with our results, Bonelli et al. (Bonelli et al.,
2005) did not find any tramadol influences on the induction of
apoptosis in cerebrospinal fluid obtained from patients (Bonelli
et al., 2005). Likewise, the decrease in ATP was consistent with the
predominant mechanism of death being necrosis, since high ATP
levels are required for apoptotic cell death (Tsujimoto 1997 ). In the
same way, the analysis of cytochrome c release revealed no
changes after exposure to tramadol/tapentadol, in comparison to
the control. Concerning the caspase activity, the weak activation of
the effector caspase-3 also suggests that a mechanism other than
apoptosis is the main responsible for cell death. Nevertheless, as
tapentadol has been shown to induce some apoptosis, caspase-9
activity was assessed. The activation of caspase-9 activity indicates
that tapentadol may also cause some apoptosis. Some drugs, such
as buprenorphine, accumulate in mitochondria, inhibiting b-oxi-
dation and mitochondrial respiration, which cause a decrease in
ATP and subsequent mitochondrial collapse (Berson et al., 2001).
Similarly, studies with high methadone concentrations in SH-SY5Y
cells have shown mitochondrial alterations, cytochrome c release,
necrotic cell death and drastic ATP reduction (more than 60%)
(Perez-Alvarez et al., 2010). Since tramadol has a positive charge in
working conditions and at physiological pH (Pinho et al., 2013), it
can accumulate within mitochondria, and the decrease of ATP and
other toxic effects caused by tramadol and tapentadol may be
caused by damage to the mitochondria. However, our results do
not indicate mitochondrial damage, since changes in membrane
potential or cytochrome c release were not observed. The
assessment of mitochondrial membrane potential did not evidence
any measurable modifications in Dcm, even at highly cytotoxic
concentrations, although ATP levels decreased significantly.
Considering the absence of effects in mitochondrial integrity,
and the detection of an accentuated decrease in ATP, the levels of
glucose and lactate were evaluated in order to ascertain changes in
energetic metabolism. Glucose and lactate intracellular levels were
shown to be increased, which indicates changes in the energetic
metabolism. It is known that tramadol therapy is associated with
an increased risk of hypoglycemia, sometimes requiring hospitali-
zation (Fournier et al., 2015), and tramadol administration is
associated with a hypoglycemic effect in type 2 diabetics (Choi
et al., 2005). The exposure of neuronal cells to tramadol activates
the insulin signalling pathway, increases insulin receptor expres-
sion, and consequently glucose uptake will be higher (Choi et al.,
2005). Our results suggest that both tramadol and tapentadol
stimulate glucose uptake, as an increase of intracellular glucose
levels was detected. Moreover, the changes found in acute
exposure may also be due to alterations in the expression levels
of enzymes involved in energetic metabolism, leading to a
bioenergetic crisis that is suggested by several authors as a
consequence of the exposure to opioids (Perez-Alvarez et al., 2010).
The exposure of mice to morphine promotes a decrease of the
expression in 3 energetic metabolism enzymes (NDUFS, LDH2 and
PDH) and a decrease in ATP levels, and these changes are
associated with withdrawal jumping and memory impairment
(Chen et al., 2007 ). In this sense, in the specific case of tramadol,
proteomic studies indicate changes in several enzymes of energy
metabolism, similarly to what happens with abuse drugs such as
heroin, cocaine and methamphetamine (Zhuo et al., 2012). In
accordance, our results have shown alterations in the expression of
LDH, NDUFS1 and CKB enzymes involved in energetic metabolism.
The activity of these enzymes is associated with ATP production,
for which the reduction of their expression will contribute to the
reduction of ATP showed in our results. NDUFS1 is a respiratory
chain enzyme, one of the enzymes of oxidative phosphorylation in
the mitochondria; LDH catalyzes the interconversion of pyruvate
and lactate; and CKB catalyzes the interconversion of creatine and
phosphocreatine. The decrease in the expression of these three
genes is also detected in rats following exposure to morphine, and
Fig. 6. ATP quantification on SH-SY5Y cells exposed to different tramadol (Tram)
and tapentadol (Tap) concentrations, for 48  h. ATP quantification was normalized
against the protein content of the extract. It was also normalized against the value
obtained in the absence of opioid, set as 1. Results are expressed as means ! SD, 10
replicates performed in 5 independent assays. ***p < 0.001, **p < 0.01.
Fig. 7. Relative expression genes, upon exposure to tramadol (Tram) or tapentadol
(Tap), for 48  h. The values were normalized against rRNA 18  S gene expression.
Expression levels were also normalized against the value obtained in the absence of
opioid, set as 1 (100%). Results are expressed as means ! SD, reflecting at least 5
independent assays. ***p < 0.001, **p < 0.01, *p < 0.05.
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has been involved in the development of morphine dependence
and memory deficits (Chen et al., 2007). In addition, the decrease in
CK expression is also associated with brain damage and is closely
associated with a neurodegenerative pathway (Streck et al., 2008).
As for CK, it has been previously reported that tramadol leads to a
decreased expression in zebrafish brain (Zhuo et al., 2012);
however, for tapentadol there are no studies, at least to our
knowledge. The decrease in the expression of NDUFS1, LDH and
CKB, along with the increased uptake of glucose after tramadol and
tapentadol exposure, denote a compromised energetic metabolism
and cause a decrease in ATP production. Our results also show
increased expression of PDK3 and ALDOC genes. Changes in the
expression of these two genes had been previously suggested in
proteomic assays in zebrafish brain after tramadol exposure (Zhuo
et al., 2012). PDK is a kinase enzyme which acts to inactivate the
pyruvate dehydrogenase (PDH) enzyme (PDH catalyses the
conversion of pyruvate to acetyl-CoA), while ALDOC is a glycolytic
enzyme, catalyzing the reversible conversion of fructose-1,6-
bisphosphate to glyceraldehyde-3-phosphate or dihydroxyacetone
phosphate. The slight increase in the expression of ALDOC enzyme
may be explained by the fact that the cell has reduced levels of ATP,
as well as considerable intracellular amounts of glucose. Therefore,
the cell increases the expression of ALDOC gene in order to further
metabolize glucose through the glycolysis pathway, so that ATP
production is enhanced, but subsequent conversion of pyruvate to
acetyl CoA is conditioned (because of the increasing PDK
expression that inactivates PDH). On the other hand, we detected
a reduction of NDUFS1 expression, reflecting that mitochondrial
respiration will be compromised. Thus, due to the increase in the
expression of PDK and decrease in NDUFS1 expression, pyruvate
will accumulate and will be converted into lactate, whose
accumulation consequently inhibits the expression of LDH. In
the future, it would be interesting to evaluate the expression of
other enzymes involved in energetic metabolism, such as ATP
synthase beta-chain, pyruvate dehydrogenase and phosphofruc-
tokinase. It would also be important to evaluate the possibility
that tramadol and tapentadol cause changes on glucose trans-
porters (GLUTs), and, as such, on glucose uptake, which would help
to understand high intracellular glucose levels. In the same way, in
vivo assays will be important in order to complement the results
obtained in vitro. The combination of all changes detected
shows that tramadol/tapentadol exposure elicits an energetic
disorder (Fig. 8). As energetic disorders are often associated with
neurodegenerative diseases (Zhuo et al., 2012), so the abuse of
these two opioids, in particular of tapentadol, must be controlled in
order to prevent neurologic damage.
5. Conclusions
Taken together, the results of the present study demonstrate
that tramadol and tapentadol exhibit neurotoxic effects in vitro,
tapentadol being more toxic in the same concentrations and
exposure times. Both drugs decreased cell viability and necrosis is
the main mechanism of cell death. Tramadol-induced cell death
does not involve apoptosis, while this mechanism is present for
tapentadol. Both drugs decrease ATP intracellular levels and
increase lactate and glucose levels, but no mitochondrial changes
were observed. Cell exposure to tramadol or tapentadol causes
changes in the expression of genes encoding for enzymes involved
in glucose metabolism, leading to a bioenergetic crisis.
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A B S T R A C T
Tramadol and tapentadol are extensively prescribed for the treatment of moderate to severe pain. Although these
drugs are very effective in pain treatment, the number of intoxications and deaths due to both opioids is
increasing, and the underlying toxic mechanisms are not fully understood. The present work aimed to study the
potential biochemical and histopathological alterations induced by acute effective (analgesic) doses of tramadol
and tapentadol, in Wistar rats. Forty-two male Wistar rats were divided into different groups: a control,
administered with normal saline solution, and tramadol- or tapentadol-treated groups (10, 25 or 50 mg/kg –
typical effective analgesic dose, intermediate and maximum recommended doses, respectively). 24 h after
intraperitoneal administration, biochemical and oxidative stress analyses were performed in blood, and
specimens from brain, lung and heart were taken for histopathological and oxidative stress studies. Both drugs
caused an increase in the AST/ALT ratio, in LDH, CK and CK-MB activities in serum samples, and an increase in
lactate levels in serum and brain samples. Oxidative damage, namely protein oxidation, was found in heart and
lung tissues. In histological analyses, tramadol and tapentadol were found to cause alterations in cell
morphology, inflammatory cell infiltrates and cell death in all tissues under study, although tapentadol caused
more damage than tramadol.
Our results confirmed the risks of tramadol exposure, and demonstrated the higher risk of tapentadol,
especially at high doses.
1. Introduction
Pain is a symptom associated with several pathologies, and opioids
are currently used for the treatment of its moderate to severe forms.
However, besides analgesia, the activation of μ-opioid receptors (MOR)
also causes side effects such as central nervous system (CNS) depres-
sion, nausea, dependence and addiction (DePriest et al., 2015; Harrison
et al., 1998; Kosten and George 2002). Hence, the use of non-classical
opioids, which combine MOR agonist activity with monoamine reup-
take blocking, has been seen to improve analgesia and decrease the side
effects (Pergolizzi et al., 2012; Power 2011; Singh et al., 2013;
Tzschentke et al., 2014; Vadivelu et al., 2010). Tramadol and tapenta-
dol are two synthetic opioid analgesics, with a dual mechanism of
action − opioid agonist action and monoamine reuptake inhibition
(Barbosa et al., 2016; Mercier et al., 2014).
Tramadol (1RS, 2RS)-2-[(dimethylamino)methyl]-1-(3-methoxy-
phenyl)-cyclo-hexanol is a racemic mixture of two enantiomers,
(−)-tramadol and (+)-tramadol, that have two distinct but comple-
mentary mechanisms of action (Grond and Sablotzki 2004; Raffa et al.,
2012). Tramadol is responsible for moderate MOR agonist activity, and
noradrenaline (NA) and serotonin (5-HT) reuptake inhibition, and its
analgesic activity is predominantly provided by the O-desmethyltrama-
dol (M1) active metabolite (Duthie 1998; Gillen et al., 2000; Grond and
Sablotzki 2004; Lai et al., 1996; Leppert 2011). Tapentadol (3-[(1R,2R)-
http://dx.doi.org/10.1016/j.tox.2017.05.003
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3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol) is a single and ac-
tive molecule, without active metabolites (Bourland et al., 2010;
Hartrick and Rozek 2011; Raffa et al., 2012). Tapentadol effect on
the inhibition of 5-HT reuptake is less pronounced than that of
tramadol, which reduces the risk of serotonin syndrome (Giorgi et al.,
2012; Hartrick and Rozek 2011; Meske et al., 2014; Raffa et al., 2012;
Steigerwald et al., 2013; Tzschentke et al., 2014).
Although tramadol and tapentadol have low incidence and intensity
of side effects, addiction, respiratory depression and fatal cases have
been reported (Clarkson et al., 2004; Costa et al., 2013; Dinis-Oliveira
et al., 2012; Giorgi et al., 2012; Larson et al., 2012; Pinho et al., 2013;
Ryan and Isbister 2015; Shadnia et al., 2008). Therefore, it is important
to assess the potential toxicity of these compounds. Previous reports
showed that acute gavage administration of tramadol LD50 induced rat
brain alterations, including brain congestion, edema and inflammatory
cellular infiltrates (Samaka et al., 2012). Chronic use of tramadol in
increasing doses was also associated with neuronal degeneration in the
rat brain, which has a possible contribution to cerebral dysfunction
(Atici et al., 2005, 2004; Awadalla and Salah-Eldin, 2016). Repeated
tramadol administration has also been shown to cause lung damage
(Awadalla and Salah-Eldin, 2016). Moreover, in vitro acute exposure
assays in a human neuronal model showed that both compounds,
tramadol and tapentadol, cause toxicity (Faria et al., 2016). However,
concerning tapentadol there are no studies evaluating its toxicity in in
vivo models. Additionally, myocardial damage may be associated with
the inhibition of NA reuptake (Vadivelu et al., 2011), and therefore it is
important to evaluate the potential cardiovascular damage after
tramadol and tapentadol exposure. Hence, it is relevant to assess the
toxic effects of different doses, including overdoses, particularly con-
cerning neurotoxicity and central nervous system dysfunction, and lung
and heart damage, upon tramadol and tapentadol administration, in
order to evaluate their safety. Therefore, the present work aimed to
study biochemical changes, oxidative damage and histopathological
toxicity in brain, lung and heart of rats exposed to a single dose,
corresponding to a typical effective analgesic dose, an intermediate
dose and the maximum recommended daily dose, of tramadol or
tapentadol.
2. Materials and methods
2.1. Animals
In this study, 42 male Wistar rats were used. Animals (aged 8 weeks)
were obtained from the IBMC – i3S Animal House (Oporto, Portugal),
weighing between 250 and 275 g. Animals were kept in standard
laboratory conditions (12/12 h light/darkness, 22 ± 2 °C room tem-
perature, 50–60% humidity) for at least 1 week (quarantine) before
starting the assays. Animals were allowed access to tap water and rat
chow ad libitum during the quarantine period. Animal experimentation
was performed accordingly to the Portuguese Agency for Animal
Welfare (general board of Veterinary Medicine), in compliance with
the Institutional Guidelines and the European Convention. All experi-
mentation was conducted in conformity with ethical and human
principles of research, complying with the current Portuguese laws
and in line with the recommendations of the National Council of Ethics
for the Life Sciences (CNECV).
2.2. Tramadol and tapentadol exposure
Animals were divided into 7 groups of 6 animals each. The different
groups were exposed to different tramadol hydrochloride (Sigma-
Aldrich) or tapentadol hydrochloride (Deltaclon) doses, by intraperito-
neal (ip) administration. Group I was used as control, receiving normal
saline solution (0.9% NaCl); groups II, III and IV were injected with 10,
25 and 50 mg/kg tramadol, respectively; groups V, VI and VII were
injected with 10, 25 and 50 mg/kg tapentadol, respectively. 10, 25 or
50 mg/kg correspond to a typical analgesic dose, an intermediate dose
and the maximum recommended daily dose, respectively, as will be
discussed in the “Results” section. Tramadol and tapentadol doses were
delivered in a volume of 1 mL of normal saline. After ip administra-
tions, animals were individually housed in metabolic cages, for 24 h,
and during the exposure period they were provided with water ad
libitum, but not food, and monitored.
2.3. Surgical procedures and sample collection
Twenty-four hours after administrations, rats were sacrificed
through anesthesia with sodium thiopental (B. Braun Portugal,
60 mg/Kg, ip). Then, blood samples were drawn by cardiac puncture,
using a heparinized needle. Blood was centrifuged (3000g, 4 °C, 10 min)
and serum was separated and stored (−80 °C) for further biochemical
analysis (aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatine kinase (CK), creatine kinase isoform MB (CK-MB),
glucose, lactate and lactate dehydrogenase (LDH)). Brain cortex, lungs
and heart were removed, dried, weighed and processed.
2.4. Tissue processing for biochemical analysis
Brain cortex, lung and heart samples were homogenized using an
Ultra-Turrax® homogenizer with 1:4 (m/v) of ice-cold 50 mM phos-
phate buffer (KH2PO4 + Na2HPO4·H2O), pH 7.4. Homogenates were
centrifuged at 4000g, 4 °C, for 10 min. Supernatants were aliquoted and
stored at −80 °C for protein, catalase (CAT) and superoxide dismutase
(SOD) quantification and biochemical analyses (CK, lactate, LDH and
proteins). 10% perchloric acid was added in a proportion of 1:1 to one
aliquot of each homogenate. Then, samples were centrifuged at
13,000g, 4 °C, for 10 min. The supernatants were stored at −80 °C for
the quantification of lipid peroxidation (LPO), and the pellets were used
for quantification of carbonyl groups. Other aliquots of brain cortex,
lungs and heart were homogenized, using an Ultra-Turrax® homogeni-
zer, with 1:3 (m/v) of ice-cold isotonic buffer (300 mM sucrose, 10 mM
HEPES, 2 mM EDTA) pH 7.9, and incubated for 15 min on ice, for
further quantification of caspase 3 activity. After homogenization, the
sample was vortexed and then centrifuged at 850g, 4 °C, for 10 min. The
resulting supernatant was collected, and the pellets were resuspended
in 500 μL ice-cold isotonic buffer, and again incubated for 15 min on ice
and centrifuged at 14000g, 4 °C, for 10 min. The supernatant was
collected and combined with the first supernatant. The supernatants
were stored at −80 °C for protein and caspase 3 quantifications.
2.4.1. Biochemical analysis
2.4.1.1. Biochemical parameters. Biochemical parameters (AST, ALT,
CK, CK-MB, lactate, LDH, glucose and proteins) were quantified in a
Prestige 24i automated analyser (Tokyo Boeki) as previously described
(Costa et al., 2015), using 2 appropriate calibrators, which were diluted
to plot a standard curve with 5 points. A quality control was also used.
Results were normalized against the control group, and also against
protein content in brain samples.
2.4.1.2. Measurement of toxicity biomarkers. LPO was evaluated using
the thiobarbituric acid-reactive substances (TBARS) methodology
(Buege and Aust, 1978) and the results were expressed as nanomoles
of malondialdehyde (MDA) equivalents per gram of protein. Protein
carbonyl groups (ketones and aldehydes) were measured according to
Levine et al. (Levine et al., 1994), with the results being expressed as
nanomoles of 2,4-dinitrophenylhydrazine (DNPH) incorporated per
gram of protein. CAT and SOD activity was determined according to
the method of Aebi (Aebi, 1984) and of McCord and Fridovich (McCord
and Fridovich, 1969), respectively. The results were expressed in
enzyme units per gram of protein and were normalized against the
control group. Caspase 3 activity was determined as described by Faria
et al. (Faria et al., 2016), using caspase 3 peptide substrate Ac-DEVD-
J. Faria et al. 7R[LFRORJ\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pNA (Sigma-Aldrich) (to a final concentration of 80 μM). Results were
expressed in enzyme units per gram of protein. All results were
normalized against the control group.
2.5. Tissue processing for histopathological examinations
Brain cortex, lung and heart samples were subjected to routine
procedures for fixing, washing, dehydration and paraffin embedding as
previously described by Dinis-Oliveira et al. (Dinis-Oliveira et al.,
2006a, 2006b). Hematoxylin and eosin (H & E)-stained slides were
prepared by standard methods and were analyzed by light microscopy,
using 100× and 600× magnifications (Nikon Eclipse TE2000-U
microscope equipped with a DXM1200F digital camera and controlled
by Nikon ACT-1 software). Photos were taken from representative
fields.
2.6. Statistical analysis
Results were expressed as means ± SD. The graphics were plotted
using GraphPad Prism® version 7.0a. Statistical analyses were per-
formed by analysis of variance (ANOVA). Post-hoc analysis was
performed through Dunnett’s multiple comparisons test. P values lower
than 0.05 were considered as statistically significant.
3. Results
3.1. Biochemical alterations upon tramadol and tapentadol exposure
Wistar rats were exposed to different tramadol and tapentadol
doses, in order to evaluate the potential toxicity and biochemical
alterations caused by these opioids. Doses were selected in order to
assess changes, after a single administration, when a typical effective
dose and intermediate and maximum recommended doses are adminis-
tered. Doses were established estimating the human equivalent dose
(HED): (animal dose (mg/kg) = human equivalent dose (mg/
kg)× 6.2) (Nafea et al., 2016; Nair and Jacob 2016; Reagan-Shaw
et al., 2008), considering that an average human adult weighs 60 kg, as
well as the LD50 values reported (Matthiesen et al., 1998), concentra-
tions reported in intoxication cases (Kemp et al., 2013), and the human
recommended daily dose (Barbosa et al., 2016). Groups II and V were
exposed to 10 mg/kg, which is an effective dose corresponding to a
single dose of 100 mg in humans, and less than the maximum
recommended daily dose (400 mg per day for tramadol, and
600–700 mg per day for tapentadol) (Barbosa et al., 2016; Matthiesen
et al., 1998; Singh et al., 2013; Tzschentke et al., 2014). Indeed, 100 mg
administered in a 60 kg-human correspond to a 1.67 mg/kg dose.
Applying the HED calculation formula mentioned before, 1.67 mg/kg
(human dose) is equal to 10.35 mg/kg (rat dose), when multiplied by a
6.2 factor. Groups IV and VII received the maximum recommended
dose (50 mg/kg) for rats, through ip administration (Matthiesen et al.,
1998). Groups III and VI received an intermediate dose (25 mg/kg).
Following exposure for 24 h, biochemical alterations were analyzed
in serum samples (Fig. 1). The AST activity, AST/ALT ratio and LDH
activity significantly increased when intermediate and higher doses of
tramadol (25 mg/kg and 50 mg/kg) were administered, but not with
the lower effective (analgesic) dose. After tapentadol exposure, AST and
LDH activities also significantly increased after the exposure to the
intermediate and maximum doses (25 mg/kg and 50 mg/kg), but the
AST/ALT ratio only significantly increased with the intermediate dose
(25 mg/kg). CK activity and lactate concentration significantly in-
creased at the highest dose (50 mg/kg), with this increase being higher
upon tapentadol exposure, and CK-MB activity also increased at the
highest dose (50 mg/kg) of both. Glucose concentration did not change
significantly after a 24-h exposure to the doses tested. The typical
effective dose (10 mg/kg) did not lead to significant differences
comparatively with the control group.
Besides blood, biochemical parameters were also analyzed in
cerebral cortex samples (Fig. 2). LDH activity increased significantly
after exposure to 50 mg/kg tapentadol, and lactate concentration
increased significantly after exposure to 50 mg/kg tramadol and 25
and 50 mg/kg tapentadol. CK activity did not change significantly after
exposure to the doses tested, for 24 h.
3.2. Tramadol and tapentadol increase protein oxidation in lung and heart
tissues
In order to evaluate possible oxidative damage and activation of
apoptosis, caused by an acute exposure to tramadol and tapentadol, the
concentrations of protein carbonyl groups and LPO, as well as SOD,
CAT and caspase 3 activities were analysed in brain cortex, lung and
heart samples. In brain cortex samples taken from rats exposed to
tramadol or tapentadol, oxidative damage was not detected (Fig. 3).
Interestingly, at low doses of both compounds (10 or 25 mg/kg), there
was a reduction in LPO, and exposure to tramadol caused a decrease in
protein carbonyl groups at all doses tested. Thus, these compounds do
not appear to induce brain lipid oxidative damage in an acute exposure,
and possibly have a protective effect for lipid oxidation, especially at
low doses. In lung samples (Fig. 3), analysed after rat exposure to
tramadol or tapentadol, no alterations in LPO were detected. However,
a significant increase in protein carbonyl groups was detected after
exposure to 50 mg/kg tramadol and 25 and 50 mg/kg tapentadol. The
results of oxidative damage evaluation in the heart, upon acute
exposure to tramadol or tapentadol, show a significant increase in
protein carbonyl groups at the highest doses (50 mg/kg tramadol and
25 and 50 mg/kg tapentadol) (Fig. 3). In the lower effective dose these
compounds showed a protective effect. Regarding LPO, in heart
samples no changes were detected in comparison to the control group.
Concerning SOD and CAT, no changes were detected in their brain,
heart and lung activity, compared to the control (data not shown).
Regarding the assessment of caspase 3 activity in brain cortex and
lung samples, no increase was detected relative to the control for both
opioids (Fig. 4). However, in heart samples from rats exposed to
tramadol at all doses, a decrease in caspase 3 activity was detected
compared to the control group. In heart samples from rats exposed to
tapentadol, no changes were detected, with respect to the control
group.
3.3. Tramadol and tapentadol cause neural degeneration and damage to the
lung and heart
Brain cortex (Fig. 5), lung (Fig. 6) and heart (Fig. 7) samples of rats
treated with tramadol or tapentadol, and the control group, were
investigated histologically. All groups treated with tramadol or tapen-
tadol were compared with negative control tissues (non-treated rats).
After treatment with 10 mg/kg tramadol in brain tissues, swollen
neurons and vacuolization were observed (Fig. 5). The increment in
tramadol dose (25 and 50 mg/kg) caused an increase in damage/
histological changes. At the 25 mg/kg tramadol dose, degenerated
neurons, with darker staining, were observed, as well as a lower
definition of the nuclear membrane, which appeared irregular in shape.
In parallel, smaller cells were observed, suggesting the occurrence of
cell death. In addition, after administration of 50 mg/kg tramadol,
there was an increased number of degenerated neurons, more darkly
stained, and showing focal aggregation of the glial cells (focal gliosis).
In animals treated with tapentadol, brain damage, observed through
histology, was more pronounced and detected at all doses. After a
10 mg/kg tapentadol dose, swollen neurons and neurons with marked
cytoplasmic vacuolization were observed, besides a lower definition of
the nuclear membrane, appearing irregular in shape. In higher tapen-
tadol doses (25 and 50 mg/kg), neuronal damage was more pro-
nounced, with various neurons with darker staining, indicating neural
degeneration, as well as glial activation with microglial proliferation.
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Fig. 1. Activities of: aspartate aminotransferase, aspartate aminotransferase/alanine transaminase ratio, lactate dehydrogenase, creatine kinase, creatine kinase isoform MB; and glucose
and lactate concentrations in rat serum samples after exposure to tramadol or tapentadol for 24 h. Results were normalized against the value obtained in the absence of opioid (control
group), set as 1. Results are expressed by means ± SD. ***p < 0.001, **p < 0.01, *p < 0.05.
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Lung histological analysis, after H & E staining, is shown in Fig. 6.
Tramadol exposure causes lung injury, and the increase in its dose led
to an increase in histological changes. After 10 mg/kg doses, interstitial
changes (congestion) were observed; in addition, after 25 and 50 mg/kg
administration, intra-alveolar hemorrhage, alveolar collapse and de-
struction were observed. Acute exposure to tapentadol caused several
alterations at all doses, such as inflammatory cell infiltrates, interstitial
changes (hemorrhage) and, at higher doses (25 and 50 mg/kg), alveolar
collapse was observed.
Fig. 7shows the histological analysis of heart tissue samples. After
treatment with 10 mg/kg tramadol, no alterations or damage were
observed. Nevertheless, at intermediate and higher doses (25 and
50 mg/kg tramadol), altered cardiomyocytes and inflammatory cell
infiltrates were observed, and loss of striation of cardiomyocytes was
detected. In heart samples taken from rats exposed to tapentadol,
alterations were observed at all doses. At the lowest dose (10 mg/kg
tapentadol), loss of cardiomyocyte striation and inflammatory cell
infiltrates were observed, and altered cardiomyocytes were also de-
tected along with dose increase.
4. Discussion
The therapeutic use of opioids, namely tramadol and tapentadol, is
increasing nowadays. Cases of toxicity have been reported, emphasizing
the need to understand their toxicity mechanisms (Barbosa et al., 2016;
Clarkson et al., 2004; Kemp et al., 2013). In this context, it is important
to use animal models to study the toxic effects and particularly to study
the possibility of brain damage, since these opioids target the CNS.
Especially for tapentadol, this is the first study that evaluates rat brain,
lung and heart alterations resulting from its exposure. Moreover, this is,
to our knowledge, the first study dealing with the comparative brain,
pulmonary and cardiac toxic potential of tramadol and tapentadol in an
in vivo model.
The analysis of biochemical parameters in blood samples, following
24 h of exposure, showed changes in several parameters. AST is an
important enzyme in amino acid metabolism, being found in several
organs, such as heart, liver, muscle and brain. Serum AST/ALT ratio is
commonly measured as a clinical biomarker for liver and muscle
damage. Given the high AST/ALT activity ratio obtained following
administration of tramadol and tapentadol, reflecting a higher increase
in AST activity than in that of ALT, it is possible that muscle injury is
happening. Increases in serum AST activity, upon exposure to tramadol
in different dosages and periods, have already been described by
different authors (Atici et al., 2005; El Fatoh et al., 2014; Ezzeldin
et al., 2014; Saleem et al., 2014; Youssef and Zidan 2015). Increased
AST activity relative to that of ALT was reported previously in a case of
human tramadol intoxication (Wang et al., 2009). Increases in AST
activity are also associated with the exposure to other opioids, such as
morphine and heroin (Atici et al., 2005). In the highest tapentadol dose,
we observed a higher increase in ALT activity, possibly denoting liver
injury, in addition to muscle damage. Consequently, the AST/ALT ratio
is lower than for other doses. However, for tapentadol there are no
studies on the effect on serum AST levels. Thus, the results suggest that
tramadol and tapentadol may cause muscle damage, most likely in the
cardiac muscle, and with more pronounced effect at toxic doses. LDH is
an enzyme that catalyzes the interconversion of lactate to pyruvic acid,
as it converts NAD+ to NADH and back. Tissue breakdown, such heart
muscle, releases LDH; consequently, serum LDH activity can be
measured as a tissue breakdown biomarker. Increased serum LDH
activity, after exposure to tramadol, has been described by Atici et al.
(Atici et al., 2005), although the increase was not significant. Other
opioids, such as morphine and heroin, are associated with an increased
LDH activity, as well as ALT and AST activities, after prolonged
exposures (Atici et al., 2005; Borzelleca et al., 1994). Similarly, this
increased LDH activity in serum also suggests the occurrence of cell
lysis, and that the damage caused by tramadol and tapentadol is evident
from 25 mg/kg. Although toxicity on metabolizing organs was not the
focus of this study, the alterations in AST/ALT levels, as well in LDH
activity, may additionally suggest liver toxicity, since these markers are
not specific. Thus, such possibility cannot be ruled out and deserves to
Fig. 2. Lactate dehydrogenase and creatine kinase activities, and lactate concentration in
rat brain cortex samples after exposure to tramadol or tapentadol for 24 h.
Quantifications were normalized against the protein content. They were also normalized
against the value obtained in the absence of opioid (control group), set as 1. Results are
expressed by means ± SD. ***p < 0.001, **p < 0.01, *p < 0.05.
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be evaluated in future assays. In turn, CK catalyzes the interconversion
of creatine and phosphocreatine. In the CK activity assay, the activity of
all isoforms is measured, whereas CK-MB is a specific cardiac marker.
Therefore, the increase in CK-MB activity, together with the increased
AST and LDH activities, suggest that tramadol and tapentadol cause
damage to the cardiac muscle. Moreover, in situations of death from
tramadol exposure, myocardial damage is reported as one of the
autopsy findings (Mannocchi et al., 2013), and increased CK and CK-
Fig. 3. Lipid peroxidation and protein carbonyl group concentrations in rat brain cortex, lung and heart samples after exposure to tramadol or tapentadol for 24 h. Quantifications were
normalized against the protein content. They were also normalized against the value obtained in the absence of opioid (control group), set as 1. Results are expressed by means ± SD.
***p < 0.001, *p < 0.05.
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MB activities were described in tramadol overdose (Wang et al., 2009).
Serum lactate concentrations increased after exposure to the highest
doses. In vitro studies by our group have shown that an acute exposure
to tramadol and tapentadol causes an increase in lactate levels as a
result of alterations in the expression levels of enzymes involved in
energetic metabolism (Faria et al., 2016). These changes, and the
consequent bioenergetic crisis resulting from the exposure to opioids,
including tramadol and tapentadol, have been suggested by several
authors (Faria et al., 2016; Perez-Alvarez et al., 2010; Zhuo et al.,
2012). In fact, changes in energetic metabolism and cell lysis cause an
increase in lactate levels, which is more evident at the highest dose
Fig. 4. Caspase 3 activity in brain cortex, lung and heart samples after exposure to
tramadol or tapentadol for 24 h. Quantifications were normalized against the protein
content. They were also normalized against the value obtained in the absence of opioid
(control group), set as 1. Results are expressed by means ± SD. ***p < 0.001.
Fig. 5. Microscopy analysis, after staining with hematoxylin and eosin, of brain cortex
samples from control Wistar rats and rats acutely exposed to different tramadol or
tapentadol doses. After tramadol exposure, several cell alterations are observed, such as
swollen neurons (crossed arrows) and vacuolization (long arrows), lower definition of
nuclear membranes, appearing irregular in shape (arrow heads), degenerated neurons,
with darker staining (short arrows) and aggregation of the glial cells (star). After exposure
to tapentadol several cell alterations are observed, in all conditions, such as swollen
neurons (crossed arrows) and marked cytoplasmic vacuolization (long arrows), lower
definition of nuclear membrane, appearing irregular in shape (arrow heads), activation of
glial cells (stars) and neurons with darker staining (short arrows), indicating neural
degeneration. Magnifications 100× and 600×; scale bar, 20 μm.
Fig. 6. - Microscopy analysis, after hematoxylin and eosin staining, of lung tissue samples
from control Wistar rats and rats acutely exposed to different tramadol or tapentadol
doses. After the 10 mg/kg tramadol dose, interstitial changes – congestion (crossed
arrow) – were detected; at the 25 mg/kg dose, interstitial changes comprising congestion
(crossed arrow), intra-alveolar hemorrhage (arrow) and alveolar collapse (star) were
observed; in addition, at the higher tramadol dose (50 mg/kg), alveolar collapse and
destruction (star) were observed. After exposure to tapentadol, several cell alterations are
observed, in all conditions, such as interstitial changes – hemorrhage (crossed arrow) and
inflammatory cell infiltrates (arrow). At 25 mg/kg and 50 mg/kg tapentadol doses,
alveolar collapse (star) was observed. Magnifications 100× and 600×; scale bar, 20 μm.
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analyzed (50 mg/kg).
In parallel, oxidative stress parameters were studied, and histologi-
cal analyses were performed in brain, lung and cardiac tissues.
Oxidative damage was detected in lung and cardiac muscle tissue, in
which we detected a significant increase in protein carbonyl groups
when tramadol and tapentadol highest dose (50 mg/kg) was used, as
well as at tapentadol intermediate dose (25 mg/kg). These results,
combined with the changes detected in biochemical parameters,
suggest that tramadol and tapentadol cause heart damage, with
tapentadol having more toxic effects. Regarding the activity of anti-
oxidant enzymes, no significant changes were detected. Nevertheless, in
assays with prolonged exposure to a low tramadol dose (1/5 of the LD50
for 4 weeks), a significant increase in LPO in brain and testicular tissues
has been found, as well as a significant decrease in the gene expression
of antioxidant enzymes (e.g., Cu Zn SOD, Mn-SOD and CAT) (Ghoneim
et al., 2014). Similarly, Awadalla and Salah-Eldin also detected an
increase in LPO in serum samples, and a decrease in GSH, SOD and CAT
expression, after chronic treatment with tramadol (Awadalla and Salah-
Eldin, 2016).
It has been previously suggested that the inhibition of NA reuptake
by tapentadol may potentially lead to adverse effects at the cardiovas-
cular level (Vadivelu et al., 2011), although such effects are not always
observed (McCarberg, 2007). In the case of heroin exposure, several
papers analyzed cardiac pathology, though also with inconsistent
results (Milroy and Parai, 2011). Histological analyses of samples
collected from heroin users have shown an increase in the number of
inflammatory cells in the myocardium in comparison to the control
group, suggesting an activation of the cellular immune system
(Dettmeyer et al., 2009). Accordingly, we also observed infiltrates of
inflammatory cells at the highest dose of tramadol and at all tapentadol
doses. However, some studies using experimental models suggest that
the treatment with tramadol relieves myocardial injuries induced by
ischemia reperfusion (Takhtfooladi et al., 2015). Even so, a study
evaluating exposure to tramadol, after surgical coronary revasculariza-
tion, concluded that tramadol may aggravate myocardial injury
(Wagner et al., 2010), so in situations upon heart surgery the use of
tramadol or tapentadol should be balanced.
In situations of death from opioid overdose, prominent intra-
alveolar hemorrhage (Milroy and Parai, 2011) may be observed, and
we also identified this finding following exposure to 25 and 50 mg/kg
tramadol and at all doses of tapentadol. Similarly to our results, Samaka
et al. described several lung alterations in albino rats after an acute
tramadol LD50 dose (Samaka et al., 2012). These authors identified
interstitial changes (such as pulmonary congestion, hemorrhage and
inflammatory cellular infiltrates) and alveolar changes (such as alveolar
damage, wall thickening and destruction) (Samaka et al., 2012).
Likewise, Awadalla and Salah-Eldin described several histopathological
alterations in rat lung, after chronic tramadol treatment (such as
inflammatory cellular infiltrates, congestion and intra-alveolar hemor-
rhage) (Awadalla and Salah-Eldin, 2016). In our study, we observed
that tapentadol is more toxic to the lung than tramadol, for the same
dose and exposure period, since it caused more marked damage at all
doses. Thus, tramadol and tapentadol use may be a potential factor for
lung function impairment, and in fact congested lung is an autopsy
finding in deaths by tramadol and tapentadol overdose (Kemp et al.,
2013).
The brain is particularly susceptible to oxidative damage, because of
its high levels of oxygen consumption; however, the analysis of
oxidative damage in the brain did not detect increased damage relative
to the control, under our experimental conditions, with these results
being consistent with our previous in vitro results, in a neuronal cell
model, which deemed that LPO is not an implied mechanism of acute
toxicity (Faria et al., 2016). Likewise, Kose et al. also did not detect
statistically significant differences regarding brain LPO levels after
tramadol administration, by the intracisternal route, in rat cerebrosp-
inal fluid (Kose et al., 2014). However, our results also evidenced that
oxidative damage to other organs is dose-dependent. Therefore, the
possibility of LPO should be considered for a prolonged exposure to
high doses, as a consequence of oxidative damage, as suggested by
several authors, concerning different opioids (Atici et al., 2005;
Awadalla and Salah-Eldin 2016; Ragab and Mohamed 2016; Zhang
et al., 2004).
The histopathological analysis of rat brain cortex after tramadol and
tapentadol exposure showed damage in all tested conditions. In this
sense, in the specific case of tramadol, histological abnormalities have
been described in the brain, after prolonged administration, by
Ghoneim et al., including darkly stained irregular pyramidal cells,
marked vacuolization, neuronal cell disorganization and hypercellular-
ity, as well as inflammatory cell infiltration (Ghoneim et al., 2014).
Awadalla and Salah-Eldin also observed several histological alterations
after chronic treatment with tramadol in brain cortex and hippocam-
pus, such as disorganization of cortical layers, degeneration and
congestion (Awadalla and Salah-Eldin, 2016). Similarly, El Fatoh
et al. (2014) also detected brain changes, such as neuronal degenera-
tion, after prolonged exposure to tramadol. In turn, Ragab and
Mohamed reported several brain alterations after exposure for several
days, such as neuronal cell disorganization, intercellular edema,
apoptotic cells, degenerative vacuolization and dark neurons with
hyperbasophilia (Ragab and Mohamed, 2016). In the same way, Nafea
et al. observed neurotoxic effects, through biochemical and histopatho-
logical analyses, in rats upon exposure to tramadol, or tramadol in
association with cannabis (Nafea et al., 2016). Consistently with our
results, 24 h after a single 300 mg/kg tramadol dose, by oral gavage,
brain alterations were observed, such as brain congestion and inflam-
matory cell infiltrates (Samaka et al., 2012). Regarding the exposure to
tapentadol, histological alterations were similar, but more pronounced,
to those observed for tramadol, which is expectable given the structural
and mechanistic similarity of both drugs (Barbosa et al., 2016). In vivo
studies showed that the combined mechanism of action of tapentadol
results in a lower inhibition of hippocampal neurogenesis than that
induced by morphine, as well as other classical opioids, which make
tapentadol a good alternative in neuropathic pain, offering a lower risk
for cognitive impairment (Meneghini et al., 2014). Nevertheless, our
Fig. 7. Microscopy analysis, after hematoxylin and eosin staining, of heart tissue samples
from control Wistar rats and rats acutely exposed to different tramadol or tapentadol
doses. At 10 mg/kg tramadol dose, no alterations were detected. At the highest doses of
tramadol (25 mg/kg and 50 mg/kg), some alterations were detected, such as altered
cardiomyocytes (arrows), inflammatory cell infiltrates (crossed arrows) and loss of
striation of cardiomyocytes. At the 10 mg/kg tapentadol dose, loss of striation of
cardiomyocytes and inflammatory cell infiltrates were observed (crossed arrows); at
the 20 mg/kg dose, altered cardiomyocytes (arrows) were observed; at 50 mg/kg doses,
altered cardiomyocytes (arrows) and inflammatory cell infiltrates (crossed arrows) were
observed. Magnifications 100× and 600×; scale bar, 20 μm.
J. Faria et al. 7R[LFRORJ\²

  
______________________________________________________________Part II- Original Research 
 59   
results support that tramadol and tapentadol cause toxicity to brain
tissues. Then, it is important to focus the attention on the toxic potential
of tapentadol, which has been underexplored. Different authors suggest
that the neuronal degeneration found in rat brains exposed to high
doses of morphine or tramadol probably contribute to brain dysfunction
(Atici et al., 2004; Ragab and Mohamed 2016). According to our
results, this also happens after tapentadol exposure. Previously, it was
suggested that brain histological changes and neuronal degeneration
result from the effect of tramadol on neuronal glucose metabolism and
the insulin signaling pathway (Ghoneim et al., 2014). Thus, the increase
in lactate levels detected in the brain, after exposure to tramadol and
tapentadol at higher doses, may contribute to neuronal degeneration.
Accordingly, our group has demonstrated, in cellular models, that
tramadol, as well as tapentadol, cause a bioenergetic crisis (Faria et al.,
2016). Consequently, metabolic changes may be responsible for some of
the neuronal damage detected.
In order to search for apoptosis evidence, caspase 3 activity was
assessed, but no increases were detected. Likewise, other in vivo studies
showed no apoptosis induction after tramadol exposure in cerebrosp-
inal fluid obtained from patients (Bonelli et al., 2005), and in vitro
studies show that necrosis is the main mechanism for cell death after
tramadol and tapentadol exposure (Faria et al., 2016). In lung samples,
analyses after chronic exposure to tramadol also did not detect a
significant increase of caspase 3 activity (Awadalla and Salah-Eldin,
2016). However, chronic treatment with tramadol was associated with
apoptotic changes in brain tissues (Awadalla and Salah-Eldin, 2016);
therefore, under chronic exposure, a possible apoptotic effect should be
considered. In this sense, a single tramadol dose provides some
protective effects, such as the decrease in brain TBARS or caspase 3
lung activity, for which tramadol may represent a better alternative in
acute treatment situations. The difference observed between tramadol
and tapentadol, in these aspects, might be due to mechanistic differ-
ences between both opioids. However, as previously discussed, pro-
longed exposure should be pondered for both compounds.
It must be added that, although the same doses were used for
tramadol and tapentadol, these are not pharmacologically equivalent,
given the distinct bioavailability of both compounds. Indeed, although
they are both rapidly absorbed after oral administration, tramadol
bioavailability is reported as approximately 68–84%, while that of
tapentadol is only 32% (Barbosa et al., 2016; Grond and Sablotzki
2004). In this study drugs were administered ip, and although it is
considered a parenteral administration since it bypasses the intestine,
the primary route of absorption is into the mesenteric vessels, which
drain into the portal vein and pass through the liver (Lukas et al.,
1971). Therefore, substances also undergo hepatic metabolism upon
intraperitoneal administration, before reaching the systemic circulation
(Lukas et al., 1971). Accordingly, in order to obtain pharmacologically
equivalent doses, tapentadol doses could actually be increased, to
compensate its lower bioavailability. However, even at the adminis-
tered doses, tapentadol was shown to induce more toxic effects; it
therefore may be anticipated that these results would be exacerbated
for higher doses. It should be also mentioned that, since a greater
toxicity was registered in tapentadol-exposed rats, differences between
tramadol and tapentadol regarding their affinity for receptors and
transporters and the potential pharmacodynamics of their metabolites,
should be considered as possible causes for the observed differences.
Lastly, it is also important to highlight that toxic changes have also
been described, in the case of tramadol, in other organs, such as liver
and kidney (Atici et al., 2005; Awadalla and Salah-Eldin 2015; Ezzeldin
et al., 2014; Saleem et al., 2014; Samaka et al., 2012), and a multiple
organ dysfunction syndrome was described in a situation of tramadol
intoxication alone (Wang et al., 2009).
5. Conclusions
The results of the present study demonstrate that tramadol and
tapentadol cause brain, pulmonary and cardiac toxic damage after a
single exposure, in typical effective doses, intermediate doses and
maximum recommended daily doses. From the histological and serum
biochemical perspective, the treatment with tapentadol seems to be
more toxic. Exposure to tramadol and tapentadol causes brain injury,
evidenced by the increased lactate levels, and histological damage,
namely swollen neurons, poorly defined nuclear membranes and
neuronal death. Pulmonary alterations, such as intra-alveolar hemor-
rhage and alveolar collapse and destruction, were also detected after
tramadol and tapentadol exposure. In addition, both drugs cause an
increase in AST, LDH and CK activities, which, together with the
histological damage to the heart, indicate that these drugs cause heart
damage. Further studies are required to evaluate the toxicity in other
organs, such as liver and kidney, as well as to perform chronic exposure
experimental designs. Indeed, it should be reminded that these opioids
are frequently prescribed on a chronic basis, for which prolonged
exposure assays would mimic clinical reality. In addition, since opioids
are often co-administered with other drugs, such as selective serotonin
re-uptake inhibitors, tricyclic antidepressants and monoamine oxidase
inhibitors, in vivo combined exposure assays would also be relevant.
The present study highlights in vivo toxic effects triggered by
tramadol and tapentadol even in acute exposure situations and
considering lower, effective doses, emphasizing that these modifica-
tions (although minor) with therapeutic dosage occur with just one
administration. Our study underlined the need for a careful selection
and prescription of both opioids, since prolonged daily therapy may
lead to damage accumulation.
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The increase in the consumption and abuse of opioid pain medications is a 
worldwide problem. Likewise, the mortality due to opioid overdose is a major issue in 
public health.  Accordingly to the Portugal Country Drug Report concerning year 2015, 
produced by the European Monitoring Centre for Drugs and Drugs Addiction, 31858 
high-risk opioid users (4.9 per 1000), and 17011 people in opioid substitution treatment 
were reported (EMCDDA 2017). Another important information reported was the 
detection of opioids in 73% of all cases where toxicological analysis was performed, 
with heroin being the most frequently detected opioid (EMCDDA 2017). In addition, 
since 2013 there has been an increasing trend in the number of deaths (EMCDDA 2017). 
Furthermore, a retrospective analysis of fatal intoxication cases by xenobiotics, 
between 2001 and 2013, autopsied in northern Portugal, reported the highest incidences 
for medicines (22.9%), with opioids being involved in 5.75% of cases, thereby 
corresponding to the fifth place on xenobiotic detection in such post-mortem analysis 
(Alves et al., 2017). 
In this regard, and considering the risk and the high number of opioid users, it is 
important to be alert for the easy access to prescription opioids, which may be an 
alternative, more accessible and cheaper, for illicit opioid users. For instance, in Iran, 
tramadol poisoning has been one of the most frequent causes of drug intoxication 
(Shadnia et al., 2008). Therefore, opioid therapy should be considered only when non-
opioid therapies are inefficient, and the patients should be maintained under medical 
supervision (O'Brien et al., 2017). In addition, and considering the high prescription of 
opioids, it is important to understand the possible toxicity triggered by them. In fact, in 
the Portuguese list of “Top 100 Active Substances with Highest Number of Packages 
in the NHS” by the “Medicine and healthcare products statistics 2014”, tramadol 
occupies the 80th position, but the formulation that combines tramadol and paracetamol 
is in the 20th position (INFARMED 2014). In turn, tapentadol is a more recent drug, 
being included in the table of narcotic drugs and psychotropic substances, amended by 
the decree-law 15/93 of 22 January in 26 March 2012 (law number 13/2012 of 26 
March), which approved the legal regime applicable to the trafficking and consumption 
of narcotic drugs and psychotropic substances.   
As previously described, tramadol and tapentadol are synthetic analgesic opioids 
with a dual and synergic mechanism of action, which increases their analgesic 
efficiency and decreases the number of side effects. Both are intensively prescribed in 
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acute and chronic contexts, for different types of pain (such as postoperative and cancer 
pain), for which their consumption in clinical settings is also increasing nowadays. 
Despite their lower incidence of side effects, as described, cases of abuse and toxicity 
were reported, and their safety should be carefully analysed. For instance, in some 
countries, such as Iran, Sweden, Ukraine, Egypt, Brazil, China, the United Kingdom 
and the United States, increased tramadol use and abuse is a problematic concern. In 
contrast, several reports suggest that tapentadol abuse is infrequent (Butler et al., 2015; 
Pergolizzi et al., 2017), which may be due to its lower MOR affinity (Tzschentke et al., 
2007). However, more studies are needed to evaluate tapentadol potential abuse, and to 
support the comparison between tramadol and tapentadol pharmacological and 
toxicological profiles. Regarding toxic effects, in addition to the more common adverse 
effects (such as dizziness, vomiting, constipation and sweating), fatal intoxications 
have been reported for both opioids (Cantrell et al., 2016; Clarkson et al., 2004; Franco 
et al., 2014; Kemp et al., 2013; Larson et al., 2012; Pilgrim et al., 2011; Shadnia et al., 
2008). Although some studies have been performed in order to analyse tramadol and 
tapentadol toxic damage in different organs, and to explain their toxicity, the 
corresponding mechanisms are not completely understood yet. Concerning tapentadol 
in particular, few studies had been accomplished to evaluate its toxicity, and little is 
known about its potential toxicity and underlying mechanisms.  
Accordingly, the work presented in this thesis was developed with the global 
objective of comparing the acute toxicity of tramadol and tapentadol, with the purpose 
of increasing the knowledge about the toxic effects of opioid therapy in target organs, 
and thus to alert the health professionals to carefully and reasonably balance opioid 
prescription.  
The work presented in CHAPTER I contributed with some advances in the 
characterization of the mechanisms of tramadol and tapentadol toxicity, and showed a 
comparative approach to the potential toxic effects of both opioids. A neuronal cell 
model (the SH-SY5Y cell line) was exposed to both opioids, at the same doses and time 
periods, to assess putative damage. After exposure, a decrease in cell viability was 
observed, showing that both compounds cause toxicity in this cell model, with 
tapentadol causing more toxic damage. In vitro results also showed that necrosis is the 
main mechanism of cell death, after tramadol and tapentadol treatment, with no 
significant increase in oxidative damage or in cytochrome c release. The toxicity 
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observed was a consequence of a bioenergetic crisis, characterized by a decrease in 
ATP intracellular levels, as well as an increase in glucose and lactate intracellular levels. 
Our results showed that the alteration in the expression of genes involved in energetic 
metabolism is an effect of tramadol and tapentadol exposure, and might be the cause of 
the bioenergetic crisis. These results are in agreement with proteomic studies that 
suggested that tramadol causes several alterations in energetic metabolism enzymes 
(Zhuo et al., 2012). Nevertheless, at least to our knowledge, we are presenting the first 
report concerning tapentadol exposure. Gene expression alterations, as a result of 
opioid exposure, were previously associated with dependence and memory deficit, as 
well as with neurodegeneration (Chen et al., 2007; Zhuo et al., 2012), so we should be 
alert to the possibility that tramadol and tapentadol may also cause such damage even 
after an acute exposure, and that it may increase when they are prescribed in high doses 
or within a chronic treatment. In addition, it is also important to emphasize that 
hypoglycemic events have been observed in real situations of tramadol medication 
(Choi et al., 2005). Nowadays, tapentadol is frequently suggested as a safer option than 
tramadol, for instance after cardiac surgery (Iyer et al., 2015). However, and 
considering our results, where tapentadol caused higher alterations in the parameters 
studied, we recommend careful and short-term prescription of both opioids, as well as 
the patient’s follow-up throughout the entire treatment period. 
Aiming at a more comprehensive analysis of the toxicity of tramadol and 
tapentadol, in vivo assays were performed, using male Wistar rats, as described in 
CHAPTER II. 24 hours after intraperitoneal administration of doses corresponding to 
a typical analgesic dose, an intermediate dose and the maximum recommended daily 
dose, the toxicological effects were assessed. The analysis of serum biochemical 
biomarkers showed that both drugs cause an increase in the AST/ALT ratio and in the 
activity of LDH, CK and CK-MB enzymes. These results suggested muscle damage, 
probably cardiac injury, as a result of the exposure to both opioids. In this context, the 
increase in the AST/ALT ratio and in CK and CK-MB activities had already been 
reported in a case of tramadol overdose; and accordingly to that, myocardial damage 
had been described in an autopsy finding, in a case of death associated to tramadol 
consumption (Wang et al., 2009). Accordingly, the increase in LDH activity suggests 
cell lysis, and the increase in CK-MB – a specific cardiac marker –, also corroborates 
the hypothesis of cardiac injury. In addition to serum analysis, histological assays were 
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performed and oxidative stress parameters were studied in brain, lung and cardiac 
tissues. Oxidative damage, through an increase in protein oxidation, was detected in 
lung and heart samples. In turn, the histological approach evidenced alterations in all 
the tissues under analysis (brain, lung and heart). Histological changes promoted by 
tramadol had previously been described by other authors, particularly in a chronic 
context (Awadalla and Salah-Eldin 2016; Samaka et al., 2012); however, we did also 
observe these alterations in an acute exposure and after exposure to tapentadol, with 
this being more toxic than tramadol. These findings, together with the in vitro results, 
support that tramadol and tapentadol cause brain toxicity, and underline the need for 
further assays concerning tapentadol toxicity. In addition, in vivo results showed an 
increase in lactate levels in brain tissue, which may reflect the bioenergetic crisis 
triggered by tramadol and tapentadol, as we had suggested in our in vitro assays (see 
CHAPTER I). Figure 1 lists the main toxic effects detected in brain, lung and heart 
specimens, after tramadol or tapentadol acute exposure, as assessed through 
biochemical and histological approaches. 
 
 
 
Figure 1: Main brain, lung and heart alterations detected after acute administration of effective 
analgesic doses of tramadol or tapentadol to Wistar rats. AST/ALT: aspartate 
aminotransferase/alanine aminotransferase; LDH: lactate dehydrogenase; CK: creatine kinase. 
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Although, in CHAPTER II, we present brain, lung and heart specific analysis, the 
multiple organ dysfunction syndrome, encompassing other organs, was previously 
described for tramadol intoxication (Wang et al., 2009). In this sense, additional studies 
by our group, reported in a paper by Barbosa et al. (2017), showed that tramadol and 
tapentadol acute administration causes hepatic and renal impairment, and once again 
tapentadol was comparatively more toxic than tramadol. For instance, an increase in 
the activity of ALT and a decrease in urea levels were observed, which, together with 
histological observations, such as sinusoidal dilatation, microsteatosis and cell 
degeneration, showed that tramadol and tapentadol cause liver damage, particularly at 
the highest dose tested (Barbosa et al., 2017). In this paper, through periodic acid-Schiff 
(PAS) staining, glycogen depletion was observed, after exposure to tramadol and 
tapentadol (Barbosa et al., 2017), in agreement with the metabolic and energetic 
changes we suggest in CHAPTER I and II, as a result of the exposure to tramadol and 
tapentadol. In the same context, changes in renal function, including proteinuria and a 
decrease in the glomerular filtration rate (GFR), were observed, while histological 
examination evidenced signs of tubular disorganization, inflammatory infiltrates and 
cell vacuolization. These results corroborate those presented in this thesis, showing that 
tramadol and tapentadol cause multi-organ toxic effects, even in an acute exposure and 
in a low-dose range.  
We highlight that the results obtained for tapentadol are particularly important, 
since, to our knowledge, there were no in vivo studies with animal models on their 
toxicity in different tissues. In addition, it is important to be alert to the toxicological 
potential, as well as to the increased risk of their abuse, when these opioids are used in 
a chronic context. Thus, it is crucial to evaluate the effects of tramadol or tapentadol 
chronic exposure. In this context, chronic tramadol administration was associated with 
memory impairment, as a consequence of increased reactive oxygen species (ROS), 
mitochondrial membrane potential (MMP) collapse, and increased cytochrome c 
release, leading to brain mitochondrial dysfunction (Mehdizadeh et al., 2017). 
Therefore, we may expect tapentadol to cause the same alterations. In fact, in order to 
minimize the potential consequences of tramadol and tapentadol therapy, in cases of 
chronic treatment, a prolonged dose interval or a dose reduction are recommended 
during the treatment (O'Brien et al., 2017). 
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Our results are also a starting point for the study of the potential increase in toxicity 
resulting from the simultaneous consumption and misuse of opioids with other drugs. 
In accordance, the concurrent use of drugs is now a trend and a worldwide problem. 
For instance, in a study that analysed a sample of 2000 Iranian adolescents, the authors 
concluded that tramadol could be a related factor or co-factor for alcohol, Cannabis and 
MDMA (3,4-methylenedioxymethamphetamine; “ecstasy”) abuse in the adolescent 
population (Nazarzadeh et al., 2014). In Portugal, Cannabis is the most frequently used 
illicit drug among young adults (15-24 years), while MDMA is the second most 
reported drug (EMCDDA 2017). 
Despite the higher incidence of simultaneous consumption of multiple drugs, the 
underlying toxic effects and corresponding cellular mechanisms are not completely 
understood yet. For instance, tramadol and MDMA co-administration may increase the 
risk of serotoninergic syndrome (SS), given the increased risk of 5-HT accumulation in 
the central nervous system (CNS). Therefore, more studies should be performed in 
order to evaluate the effects of tramadol and MDMA combination. Regarding 
tapentadol, Franco et al. (2014) reported a fatal intoxication by this opioid, suggesting 
respiratory depression, CNS depression and SS as possible mechanisms of death. 
Additionally, and although tapentadol serotonergic activity is much more limited than 
its norepinephrinergic action (Raffa et al., 2012; Tzschentke et al., 2007), Walczyk et 
al. (2016) also reported a case of probable SS after tapentadol overdose, in combination 
with other medications, in particular duloxetine and amitriptyline. These authors 
contacted Janssen Pharmaceuticals, tapentadol manufacturer, by telephone, in order to 
inquire if SS had been implied as a consequence of tapentadol intake (Walczyk et al., 
2016). The manufacturer’s senior therapeutic specialist replied that no cases were 
reported in phase 2 and 3 clinical trials; nonetheless, in post-marketing, SS had been 
reported in patients using tapentadol in combination with other serotonergic drugs 
(Walczyk et al., 2016). In this sense, further studies are needed to assess whether 
tapentadol, combined with other drugs, may cause SS. 
The possibility of drug-drug interactions should also be emphasized for all drug 
mixtures. Tramadol is metabolized by cytochrome P450 enzymes, for which 
pharmacogenetic variations may be responsible for variability in their 
pharmacokinetics, accounting for their toxicity and analgesic efficiency. In this context, 
the CYP2D6 ultra-rapid metabolizer (UM) phenotype has been associated with toxicity 
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cases, for which a 30%-decrease in tramadol dose is recommended (Barbosa et al., 
2016; Lassen et al., 2015). On the other hand, tramadol analgesic efficacy is lower in 
CYP2D6 poor metabolizers (PMs), who show increased tramadol half-life and 
decreased M1 concentrations. In these cases, an alternative drug is 
recommended  (Barbosa et al., 2016; Lassen et al., 2015). In addition, concurrent 
consumption of other drugs may increase tramadol toxicity (Barbosa et al., 2016; 
Pilgrim et al., 2010; 2011). Concerning tapentadol, since it has a simpler metabolism 
and does not require metabolic activation, it is less susceptible to cases of metabolic 
interaction. In this context, and again using the MDMA example, Jamali et al. (2017) 
concluded, in a rat model, that MDMA affects tramadol absorption, distribution and 
metabolism. Indeed, in vitro studies suggest that MDMA may inhibit the CYP2D6 
isoenzyme by competitive interaction and/or the formation of a metabolic intermediate 
(Capela et al., 2009), thereby decreasing the metabolism of tramadol when taken 
together. Accordingly, it is important to better understand the effects of drug mixtures 
in order to recognize and prevent their adverse reactions. 
The results obtained within the scope of this thesis suggest that tramadol and 
tapentadol single exposure cause toxicity in an in vitro neuronal model, as well as in 
different organs in an in vivo model. Therefore, we suggest increased education and 
awareness about opioid prescription, and that the doses are carefully adjusted to each 
patient, in ways that maximise benefit and minimise harm. Lastly, we underline the 
recommendation of other authors for the reduction of the period of opioid prescription, 
in order to decrease the risk of opioid toxicity, misuse, addiction and overdose. 
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This thesis evidenced several alterations in in vitro and in vivo models, as a result 
of tramadol and tapentadol exposure. The major conclusions are summarized below: 
 
1. Tramadol and tapentadol caused neurotoxic effects in an in vitro model, the SH-
SY5Y cell line; 
2. Tapentadol showed to trigger much more prominent toxic effects than tramadol, for 
the same concentrations and time exposure period, causing a higher decrease in cell 
viability, which is reflected in its lower IC50 value (200 µM and > 600 µM, 
respectively); 
3. The main mechanism of cell death, after exposure to both opioids, is necrosis, 
although apoptotic cells were observed after tapentadol exposure, as well as a slight 
increase in caspase 3 and 9 activities; 
4. Oxidative stress does not have a major contribution to tramadol and tapentadol toxic 
effects, given that no significant oxidative alterations in lipids and proteins were 
detected; 
5. Both opioids cause bioenergetic alterations, through an increase in intracellular 
glucose and lactate levels, and a decrease in ATP levels; 
6. Both drugs lead to alterations in the expression of genes involved in energetic 
metabolism (they decrease the expression of LDH, NDUFS1 and CKB, and 
increase the expression of PDK3 and ALDOC), leading to a bioenergetic crisis; 
7. In vivo assays, after exposure to typical effective doses, intermediate doses and 
maximum recommended daily doses, showed that tramadol and tapentadol cause 
brain, lung and heart toxicity, with tapentadol being more toxic; 
8. The AST/ALT ratio, LDH, CK and CK-MB activities and lactate levels increase in 
rat serum samples as a consequence of the treatment with tramadol and tapentadol; 
9. Tramadol and tapentadol acute treatment causes oxidative damage, at the protein 
level, in lung and heart rat tissues; 
10. Brain, pulmonary and cardiac rat tissues are affected by tramadol and tapentadol, 
evidencing signs of inflammation, cell death and cell morphology alterations after 
histological analysis. 
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Future studies are required in order to better understand the results obtained, as well 
as to continue with the study of tramadol and tapentadol toxicity.  
Concerning in vitro experiments, and the metabolic alterations reported, it would 
be important to determine the expression of other energetic metabolism enzymes, such 
as PDH and ATP synthase beta-chain. Likewise, it will also be important to study the 
toxic effects in other cell line models, such as hepatic and renal cells, in order to analyse 
the effects in metabolizing organs.  
Regarding in vivo studies, tramadol, tapentadol and their metabolites should be 
quantified in different organs, in order to evaluate their distribution and accumulation. 
In the same way, the use of a wider dose range is essential in further studies, to 
understand overdose cases. In addition, tramadol and tapentadol are often used in 
chronic treatments, and data on toxic effects resulting from chronic exposure are 
lacking, for which in vivo chronic assays should be performed. In chronic assays, 
alterations in several organs, such as metabolic and target organs, should be researched 
and correlated. Furthermore, although the simultaneous consumption of opioids with 
other drugs is an increasing trend, the underlying toxic effects and corresponding 
cellular mechanisms are not completely understood yet. Thus, in vivo combined 
exposure assays, such as with selective serotonin reuptake inhibitors, monoamine 
oxidase inhibitors and tricyclic antidepressants, would be relevant to evaluate possible 
interactions among different compounds, and the potential toxicity increase as a 
consequence of drug–drug interactions. In this context, we highlight the simultaneous 
consumption of opioids and MDMA, given that some MDMA consumers report opioid 
use in order to “come-down from ecstasy” or to minimize dysphoria following 
administration, which may increase the risk of serotoninergic syndrome, as well as the 
risk of metabolic impairment. 
Finally, the aim would be to contribute to the improvement of the patients’ quality 
of life, by individually selecting the best opioid and dose, as well as to alert the medical 
community to the potential opioid toxicity and abuse. 
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